U.S. patent application number 12/754436 was filed with the patent office on 2011-03-24 for production of foreign nucleic acids and polypeptides in sprout systems.
This patent application is currently assigned to IBIO, INC.. Invention is credited to Burt Ensley, Vadim Mett, Shailaja Rabindran, Moneim Shamloul, Vidadi Yusibov.
Application Number | 20110070609 12/754436 |
Document ID | / |
Family ID | 46323817 |
Filed Date | 2011-03-24 |
United States Patent
Application |
20110070609 |
Kind Code |
A1 |
Yusibov; Vidadi ; et
al. |
March 24, 2011 |
Production of Foreign Nucleic Acids and Polypeptides in Sprout
Systems
Abstract
The present invention provides systems and methods for producing
a nucleic acid or protein in transgenic sprouted seedlings or
sprouted seedlings engineered to transiently express a nucleic acid
or protein of interest. The sprouted seedlings of the invention are
grown in a contained, regulatable environment, wherein expression
of a pharmaceutically active protein is controlled by an
exogenously inducible promoter or a viral promoter. The sprouted
seedlings may be eaten live or preferably harvested live to
preserve the maximal biological activity of the nucleic acid or
protein.
Inventors: |
Yusibov; Vidadi; (Havertown,
PA) ; Mett; Vadim; (Newark, DE) ; Rabindran;
Shailaja; (Newark, DE) ; Shamloul; Moneim;
(Newark, DE) ; Ensley; Burt; (Sedona, AZ) |
Assignee: |
IBIO, INC.
Newark
DE
FRAUNHOFER U.S.A., INC.
Plymouth
MI
|
Family ID: |
46323817 |
Appl. No.: |
12/754436 |
Filed: |
April 5, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11353905 |
Feb 13, 2006 |
7692063 |
|
|
12754436 |
|
|
|
|
10294314 |
Nov 12, 2002 |
7683238 |
|
|
11353905 |
|
|
|
|
10770600 |
Feb 3, 2004 |
7491509 |
|
|
10294314 |
|
|
|
|
60652186 |
Feb 11, 2005 |
|
|
|
60444615 |
Feb 3, 2003 |
|
|
|
Current U.S.
Class: |
435/69.1 ;
435/91.1; 800/288 |
Current CPC
Class: |
C12N 15/8203 20130101;
A61K 38/00 20130101; C07K 14/32 20130101; C12N 15/8258 20130101;
C12N 9/16 20130101; C12N 9/88 20130101; C07K 14/61 20130101; A61K
2039/542 20130101; A61K 36/31 20130101; C12N 15/8257 20130101 |
Class at
Publication: |
435/69.1 ;
800/288; 435/91.1 |
International
Class: |
C12N 15/82 20060101
C12N015/82; C12P 21/00 20060101 C12P021/00; C12P 19/34 20060101
C12P019/34 |
Claims
1. A method for producing pharmaceutically active protein in
sprouted seedlings, comprising the steps of: infusing a sprouted
seedling with a viral expression cassette encoding a
pharmaceutically active protein and additional virus encoding
proteins, wherein a viral promoter drives expression of a nucleic
acid encoding the pharmaceutically active protein; and growing the
sprouted seedlings in a contained, regulatable environment; wherein
growing the sprouted seedlings allows for production of the nucleic
acid encoding the pharmaceutically active protein, resulting in
production of pharmaceutically active protein produced in the
sprouted seedling.
2. The method of claim 1, further comprising the step of
homogenizing live sprouted seedlings expressing the
pharmaceutically active protein in the presence of a homogenization
buffer.
3. The method of claim 1, further comprising purifying the
pharmaceutically active protein from the homogenization buffer.
4. The method of claim 1, wherein the sprouted seedling is an
edible sprouted seedling.
5. The method of claim 1, wherein the sprouted seedling is of the
Brassica species.
6. The method of claim 5, wherein the Brassica species is selected
from the group consisting of Brassica napus, Brassica rapa, and
Brassica juncea.
7. The method of claim 1, wherein the sprouted seedling is of a
plant selected from the group consisting of alfalfa, radish,
mustard, mung bean, broccoli, watercress, soybean, wheat sunflower,
cabbage, clover, and lentil.
8. The method of claim 1, wherein the contained, regulatable
environment comprises a housing unit with climate control.
9. The method of claim 8, wherein the climate control comprises
controlling any of the group selected from the temperature, the
humidity, the lighting, the water delivery, the nutrient delivery,
and the amount of gas delivery of the housing unit.
10. The method of claim 1, wherein the pharmaceutically active
protein is selected from the group consisting of antigens,
antibodies, enzymes, receptors, hormones, growth factors, growth
factor receptors, cytokines and immune system proteins, binding
proteins, transcription and translation factors, oncoprotiens or
proto-oncoprotiens, muscle proteins, myeloproteins, neuroactive
proteins, tumor growth suppressing proteins, anti-sepsis proteins,
structural proteins, and blood proteins.
11. A method for producing a pharmaceutically active protein in
sprouted seedlings, comprising the steps of: infusing a sprouted
seedling with Agrobacterium comprising a viral expression cassette
encoding a pharmaceutically active protein and additional virus
encoding proteins, wherein a viral promoter drives expression of a
nucleic acid encoding the pharmaceutically active protein; and
growing the sprouted seedlings in a contained, regulatable
environment; wherein growing the sprouted seedlings allows for
production of the nucleic acid encoding the pharmaceutically active
protein, resulting in production of pharmaceutically active protein
produced in the sprouted seedling.
12. The method of claim 11, further comprising the step of
homogenizing live sprouted seedlings expressing the nucleic acid or
protein in the presence of a homogenization buffer.
13. The method of claim 12, further comprising purifying the
nucleic acid or protein from the homogenization buffer.
14. The method of claim 1, wherein the sprouted seedling is an
edible sprouted seedling.
15. The method of claim 1, wherein the sprouted seedling is of the
Brassica genus.
16. The method of claim 15, wherein the Brassica species is
selected from the group consisting of Brassica napus, Brassica
rapa, and Brassica juncea.
17. The method of claim 1, wherein the sprouted seedling is of a
plant selected from the group consisting of alfalfa, radish,
mustard, mung bean, broccoli, watercress, soybean, wheat sunflower,
cabbage, clover, and lentil.
18. The method of claim 1, wherein the contained, regulatable
environment comprises a housing unit with climate control.
19. The method of claim 18, wherein the climate control comprises
controlling any of the group selected from the temperature, the
humidity, the lighting, the water delivery, the nutrient delivery,
and the amount of gas delivery of the housing unit.
20. The method of claim 11, wherein the nucleic acid or protein is
selected from the group consisting of antigens, antibodies,
enzymes, receptors, hormones, growth factors, growth factor
receptors, cytokines and immune system proteins, binding proteins,
transcription and translation factors, oncoprotiens or
proto-oncoprotiens, muscle proteins, myeloproteins, neuroactive
proteins, tumor growth suppressing proteins, anti-sepsis proteins,
structural proteins, and blood proteins.
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 11/353,905, filed on Feb. 13, 2006, which claims the
benefit of U.S. Provisional Patent Application No. 60/652,186,
filed Feb. 11, 2005; and which is a continuation in part of U.S.
patent application Ser. No. 10/294,314, filed Nov. 12, 2002, U.S.
Pat. No. 7,683,238; and which is a continuation in part of U.S.
patent application Ser. No. 10/770,600, filed Feb. 3, 2004, now
U.S. Pat. No. 7,491,509 which claims the benefit of U.S.
Provisional Application No. 60/444,615, filed Feb. 3, 2003. Each of
the foregoing applications is hereby incorporated by reference in
its entirety.
BACKGROUND OF THE INVENTION
[0002] The cost of pharmaceuticals is exorbitantly high and
continues to rise. Some pharmaceuticals, in addition to their high
cost, are also limited in supply, making it impossible for them to
be available to every patient that needs them. This is particularly
problematic in developing countries, where both cost and
availability hinder the distribution of pharmaceuticals to needy
populations.
[0003] Several factors contribute to the high costs of producing
pharmaceuticals, and result in the high price of the
pharmaceuticals for the consumer. A major contributing factor is
the lack of economical means of producing the product. This is
particularly true for protein and peptide-based medications.
Another contributing factor for some medications is the inability
to administer therapeutically effective amounts of the
pharmaceutical agent orally. Many pharmaceuticals can only be
administrated by injection into a particular site in the body. For
example, many immunization medications for the treatment of
allergies or infectious diseases require administration by
injection. Protein and peptide pharmaceuticals, such as human
growth hormone and insulin, can often only be administered by
injection. Another factor that contributes to the cost of many
pharmaceutical medications is their delivery to the hospital or
distribution site. Particularly in hot climates, delivery and
storage of pharmaceutical medications requires expensive
refrigeration equipment. This is a major challenge in developing
countries, where such equipment is often unavailable.
[0004] Pharmaceutical proteins and peptides have been produced in a
wide variety of hosts. Many therapeutic proteins have been produced
in heterologous expression systems including prokaryotes such as
Escherichia coli and Bacillus subtilis, and eukaryotes such as
yeast, fungi, insect cells, animal cells, and transgenic animals.
Bacterial expression systems are relatively easy to manipulate and
the yield of the product is high. However, mammalian proteins often
require extensive posttranslational modification for functional
activity, which can be a limiting factor in bacterial expression
systems. Cell culture systems such as mammalian, human, and insect
cell culture systems are more convenient for the production of
complex proteins. However, long lead times, low recovery of the
product, possible pathogen transfer, and high capital and
production costs present serious concerns. Transgenic animals may
provide an unlimited supply of complex proteins. Unfortunately,
this system is limited by the long period of time it takes to
generate new and improved products and the risk of pathogen
transfer to human subjects.
[0005] The economic and biochemical limitations to producing
pharmaceutical proteins and peptides in prokaryotic and eukaryotic
cells, including high production costs, low yields, secretion
problems, inappropriate modifications in protein processing,
difficulties scaling up to larger volumes, and contamination have
led researchers to examine plants as new hosts for the large-scale
production of proteins and peptides with the expectation of reduced
cost. Production of proteins in transgenic plants is described, for
example, in U.S. Pat. Nos. 5,750,871; 5,565,347; 5,464,763;
5,750,871; and 5,565,347. Although plants are less expensive to
grow and harvest in bulk than prokaryotic and eukaryotic cells,
expression of the foreign gene in plant cells is typically low. In
addition, harvesting the plant typically requires breaking the
plants, for example, by removing the leaves, separating the stems
from the roots, or removing the roots. Such breakage usually
results, a process that initiates wilting of the plant part and
apoptosis of the plant. A plant undergoing apoptosis generates
proteases that contribute to the degradation of the transgenically
expressed protein before purification of the protein is even begun.
Even if the plant is to be directly consumed, the activity of the
expressed pharmaceutical protein may be reduced by harvest-induced
intercellular degradation machinery.
[0006] Another major concern associated with producing foreign
proteins in transgenic plants that are grown in open fields is the
possibility of cross-pollination with plants in the wild, making it
possible for the foreign protein to enter the food chain. The
complexity of governmental regulations surrounding agricultural
practices for transgenic plants makes it difficult to get new
transgenic plants approved for agricultural use. Furthermore, the
outdoor environment is impossible to control, making proper growth,
development, and regulation of foreign gene expression difficult to
guarantee. For example, the induction of a heat inducible, light
inducible, hormone inducible, or chemically inducible promoter
would be practically impossible in an outdoor environment. Of
course, the outdoor temperature and light levels cannot be
controlled. Additionally, hormones or chemicals sprayed on a plant
are likely to be dispersed not onto the plant, but into the
environment by wind and rain. Spaying crop fields is also quite
costly.
[0007] Rodriguez et al. (see U.S. Pat. Nos. 5,888,789; 5,889,189;
and 5,994,628) disclose production of proteins, including
pharmaceutical proteins, in grains such as barley or rice. Malting
is a process by which grain is germinated under controlled
conditions and in contained facilities to produce a product, e.g.,
a foreign protein product. The harvested product is the malted
grain, which is typically kiln-dried at between 120.degree. F. and
130.degree. F. The developmentally regulated amylase promoter
typically drives expression of foreign proteins in this system.
Although the foreign proteins can be expressed in high quantities
in this system, harvesting and administration of the protein
usually requires processing of the malted grain, which can alter
the quality of the expressed foreign protein.
[0008] There exists the need for a controlled regulatable system
for producing pharmaceutical proteins in plants that decreases the
amount of intercellular degradation of the expressed protein upon
harvest.
SUMMARY OF THE INVENTION
[0009] The present invention provides methods for producing
pharmaceutical proteins in sprouted seedlings, for example of the
Brassica species, that can be consumed or harvested live. While the
invention is described herein primarily in reference to its use for
producing pharmaceutical proteins, the invention generally finds
use for producing essentially any nucleic acid (DNA and/or RNA)
and/or protein of interest, without limitation as to the particular
use(s) of the nucleic acid or protein. For example, enzymes of use
in any of a wide variety of industrial processes or bioremediation
processes (e.g., enzymes that degrade pollutants) can be produced.
Thus the description of the invention, and the claims, are to be
considered as applying to any nucleic acid or protein of interest
even if not explicitly indicated, including those with therapeutic
applications and those without. In certain embodiments the protein
is not a nutritionally important protein. Any particular protein
may be excluded from the present invention without being named
herein.
[0010] In certain preferred embodiments, the present invention
involves growing a seed to an edible sprouted seedling in a
contained, regulatable environment, e.g., indoors. The seed is
preferably a genetically engineered seed that contains an
expression cassette encoding a pharmaceutically active protein, or
any protein or nucleic acid of interest, which expression is driven
by an exogenously inducible promoter. According to the invention, a
variety of exogenously inducible promoters can be used that are
inducible, for example, by light, heat, phytohormones, nutrients,
etc.
[0011] In related embodiments, the present invention provides
methods of producing pharmaceutically active proteins in sprouted
seedlings by first generating a seed stock for the sprouted
seedling by transforming plants with an expression cassette that
encodes pharmaceutically active protein using an Agrobacterium
transformation system, wherein expression of the pharmaceutical
protein is driven by a promoter, e.g., an inducible promoter.
Transgenic seeds are obtained from the transformed plant, grown in
a contained, regulatable environment, and the resulting sprouts
express the pharmaceutical protein. If the promoter s inducible,
expression begins following application of the appropriate
inducer.
[0012] In other related embodiments methods are provided that
involves infecting sprouted seedlings with a viral expression
cassette encoding a pharmaceutically active protein whose
expression is driven by a constitutive (or inducible) promoter. The
sprouted seedlings are grown for two to fourteen days in a
contained, regulatable environment or at least until sufficient
levels of the pharmaceutical protein have been obtained for
consumption or harvesting. The seedlings may or may not be
transgenic seedlings. Thus in certain embodiments of the invention
the genome of the seedlings comprises an expression cassette
comprising a heterologous sequence that encodes a protein of
interest or can be copied or transcribed to yield a nucleic acid of
interest. The heterologous sequence may be operatively linked to
expression signals (e.g., a promoter) sufficient to direct
production of the protein or nucleic acid.
[0013] In certain embodiments of the invention in any of its
aspects, trans-activation is used to induce or increase expression
of a heterologous sequence. For example, the expression cassette
can be an inactive expression cassette that comprises an inactive
or silenced foreign nucleic acid sequence, which is capable of
directing expression of a nucleic acid or polypeptide of interest
upon its activation. In certain embodiments of the invention
trans-activation is accomplished by infecting the sprouts with a
recombinant plant viral vector (e.g., an RNA viral vector) that
encodes a factor for activating or facilitating the expression of
an inactive or silenced foreign nucleic acid sequence. See U.S.
Ser. No. 10/832,603, entitled "Expression of Foreign Sequences in
Plants Using Trans-Activation System", which is incorporated herein
by reference, for further details of suitable methods. Such methods
include techniques based on recombination (e.g., using a Lox/Cre or
Flp/Frt recombinase system) and techniques based on proteins
comprising a DNA binding domain such as GAL4 and a transcriptional
activation domain such as VP16. It is noted that a variety of other
methods may be used for achieving trans-activation. Thus using the
trans-activation approach, expression is induced by an infection
with an exogenously applied viral agent, but the inducer itself is
produced within the host cell.
[0014] In certain embodiments of the invention in any of its
aspects, the nucleic acid or protein of interest is
post-transcriptionally and/or post-translationally processed in the
cell in which it is expressed. In certain embodiments of the
invention a protein of interest is secreted from the cell in which
it is expressed. For example, the protein may naturally comprise a
secretion signal sequence, or the coding region of a nucleic acid
that encodes the protein may be modified to include a portion that
encodes a secretion signal sequence. Secretion signal sequences are
well known in the art.
[0015] In certain embodiments of the invention in any of its
aspects a heterologous sequence that encodes a protein of interest
may be altered to employ different codons from those present in the
naturally occurring sequence, in order to improve expression in
seedlings generally and/or in seedlings of a particular species.
For example, the sequence may be codon optimized for expression in
a particular species. Methods for performing codon optimization are
known in the art.
[0016] The present invention further provides systems for producing
pharmaceutically active proteins in sprouted seedlings that include
a housing unit with climate control and a sprouted seedling
containing an expression cassette that encodes a pharmaceutically
active protein, wherein the pharmaceutically active protein is
driven by a constitutive or inducible promoter. The inventive
systems provide unique advantages over the outdoor environment or
greenhouse, which cannot be controlled. This enables the grower to
precisely time the induction of expression of the pharmaceutical
protein. It also greatly reduces the cost of producing the
pharmaceutical protein.
[0017] In a final embodiment, the present invention provides
methods of treating a mammal with a pharmaceutically active protein
expressed in sprouted seedlings by growing a seed to the sprouted
seedling stage in a contained, regulatable environment, wherein the
seed contains an expression cassette that includes an inducible
promoter; inducing expression of the pharmaceutically active
protein in the sprouted seedling; and administering the sprouted
seedling expressing the pharmaceutically active protein to the
mammal.
Definitions
[0018] "Administration" of a pharmaceutically active peptide or
protein or a therapeutically active peptide or protein to a host in
need thereof is intended as providing the pharmaceutically active
protein to such host in a manner that retains the therapeutic
effectiveness of such protein for a length of time sufficient to
provide a desired beneficial effect to such host.
[0019] "Expression" refers to transcription and/or translation of
an endogenous gene or a transgene in a plant, e.g., a sprout. The
transgene may or may not be integrated into the genomic DNA of the
plant. For example, "expression" refers to transcription and/or
translation in a plant of a gene present in a bacterial, plasmid,
or viral nucleic acid, regardless of whether the bacterial,
plasmid, or viral nucleic acid is integrated into the genomic DNA
of the plant. The gene may be a gene that is heterologous to the
bacterium, plasmid, or virus.
[0020] "Expression cassette" or "expression vector" refers to a DNA
sequence (or an RNA sequence in the case of RNA viruses or RNA
plasmids), capable of directing expression of a particular
nucleotide sequence in an appropriate host cell, including a
promoter operably linked to the nucleotide sequence of interest,
which is optionally operably linked to 3' sequences, such as 3'
regulatory sequences or termination signals. It also typically
includes sequences required for proper translation of the
nucleotide sequence if any such sequences are needed. The coding
region usually codes for a protein of interest but may also code
for a functional RNA of interest, for example, an antisense RNA or
a non-translated RNA that inhibits expression of a particular gene.
The expression cassette including the nucleotide sequence of
interest may be chimeric, meaning that the nucleotide sequence
includes more than one DNA sequence of distinct origin that are
fused together by recombinant DNA techniques, resulting in a
nucleotide sequence that does not occur naturally and that
particularly does not occur in the plant to be transformed. The
expression cassette may also be one that is naturally occurring but
has been obtained in a recombination form useful for heterologous
expression. Typically, however, the expression cassette is
heterologous with respect to the host, i.e., the particular DNA
sequence of the expression cassette does not occur naturally in the
host cell and must have been introduced into the host cell or an
ancestor of the host cell by a transformation event. The expression
of the nucleotide sequence in the expression cassette may be under
the control of a constitutive promoter or of an inducible promoter
that initiates transcription only when the host cell is exposed to
some particular external stimulus. In the case of a multicellular
organism, such as a sprouted seedling, the promoter can also be
specific to a particular tissue, organ, or stage of development. A
nuclear expression cassette is usually inserted into the nuclear
genome of a plant and is capable of directing the expression of a
particular nucleotide sequence from the nuclear genome of the
plant. A plastid expression cassette is usually inserted into the
plastid genome of a plant and is capable of directing the
expression of a particularly nucleotide sequence from the plastid
genome of the plant. In the case of a plastid expression cassette,
for expression of nucleotide sequence from a plastid genome,
additional elements, i.e., ribosome binding sites, or 3' stem-loop
structures that impede plastid RNA polyadenylation and subsequent
degradation may be required.
[0021] In certain embodiments of the invention the expression
cassette comprises a promoter that is a minimal promoter such as a
TATA element, and presence of a trans-activating factor may be
necessary to direct expression of the nucleotide sequence,
particularly to direct high level expression. For example, the
expression cassette may comprise a DNA region for binding of a
transcriptional activator. Such expression cassettes, and the
promoters therein, are referred to as being "activatable".
[0022] A "gene" is a coding sequence and associated regulatory
sequences, wherein the coding sequence is transcribed into RNA,
such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA.
Examples of "regulatory sequences" are promoter sequences, 5' and
3' untranslated sequences, and termination sequences. In addition,
introns and exons may also be included. In certain preferred
embodiments, the gene is the coding sequence and the associated
regulatory sequences are heterologous sequences.
[0023] A "food" or "food product" is a liquid or solid preparation
of the sprouted seedlings of the invention that can be ingested by
humans or other animals. Preferably, the terms include preparations
of the raw or live sprouted seedlings and sprouted seedlings that
may be fed live directly to humans and other animals. Materials
obtained from a sprouted seedling are intended to include a whole
edible sprouted seedling that can be ingested by a human or other
animal The term may also include any processed sprouted seedling
together with a nutritional carrier that is fed to humans and other
animals. Processing steps include steps commonly used in the food
or feed industry. Such steps include, but are not limited to
concentration or condensation of the solid matter of the spourted
seedling to form, for example, a pellet, production of a paste,
drying, or lyophilization, or may be produced by cutting, mashing,
or grinding of the plant to various extents, or by extraction of
the liquid part of the plant to produce a soup, a syrup, or a
juice. A processing step can also include cooking, e.g., steaming,
the sprouted seedlings.
[0024] "Heterologous sequences," as used herein, means of different
natural origin or of synthetic origin. For example, if a host cell
is transformed with a nucleic acid sequence that does not occur in
the untransformed host cell, that nucleic acid sequence is said to
be heterologous with respect to the host cell. The transforming
nucleic acid may include a heterologous promoter, heterologous
coding sequence, or heterologous termination sequence.
Alternatively, the transforming nucleic acid may be completely
heterologous or may include any possible combination of
heterologous and endogenous nucleic acid sequences. Similarly,
heterologous refers to a nucleotide sequence derived from and
inserted into the same natural, original cell type, but which is
present in a non-natural state, e.g., a different copy number, or
under the control of different regulatory elements. The term
"heterologous" applies to cells, including plant and bacterial
cells, and also to plasmids, plastids, and viruses.
[0025] A "host" is an animal to whom a pharmaceutically active
protein of the present invention is administered. Such an animal is
also referred to herein as a "subject". The term "animal" covers
all vertebrates, life forms, humans, bovines, ovines, porcines,
canines, felines, ferrets, rodents, primates, fish, birds, e.g.,
poultry and the like. Particularly preferred animals are mammals.
The term "host" can also mean the cell (e.g., the plant cell)
expressing the pharmaceutical protein.
[0026] An "inactive expression cassette" or "inactive expression
vector" is a DNA or RNA sequence that comprises an inactive or
silenced foreign nucleic acid sequence, which is capable of
directing expression of a nucleic acid or polypeptide of interest
upon its activation. Generally, an inactive expression cassette has
the properties of an expression cassette as described above, except
that the sequence that codes for a nucleic acid or polypeptide of
interest may not be operatively linked to a promoter, e.g., it may
be separated from the promoter (or from another regulatory element)
by an intervening nucleic acid region. Operative linkage occurs
following a recombination event, so that expression then occurs.
Such as expression cassette is referred to as being
"activatable".
[0027] The term "inducible promoter," means a promoter that is
turned on by the presence or absence of a particular stimulus that
increases promoter activity directly or indirectly. Some
non-limiting examples of such stimuli include heat, light,
developmental regulatory factors, wounding, hormones, and
chemicals, e.g., small molecules. One example of a light-inducible
promoter is the ribulose-5-phosphate carboxylase promoter.
Chemically-inducible promoters also include receptor-mediated
systems, e.g., those derived from other organisms, such as
steroid-dependent gene expression, the Lac repressor system and the
expression system utilizing the USP receptor from Drosophila
mediated by juvenile growth hormone and its agonists, described in
WO 97/13864, incorporated herein by reference, as well as systems
utilizing combinations of receptors, e.g., as described in WO
96/27673, also incorporated herein by reference. Additional
chemically inducible promoters include elicitor-induced promoters,
safener-induced promoters as well as the alcA/alcR gene activation
system that is inducible by certain alcohols and ketones (WO
93/21334; Caddick et al. (1998) Nat. Biotechnol. 16:177-180, the
contents of which are incorporated herein by reference). Wond
inducible promoters include promoters for proteinase inhibitors,
e.g., proteinase inhibitor II promoter from potato, and other
plant-derived promoters involved in the wound response pathway,
such as promoters for polyphenyl oxidases, LAP, and TD. See, e.g.,
Gatz "Chemical Control of Gene Expression," Ann. Rev. Plant
Physiol. Plant Mol. Biol. (1997) 48:89-108, incorporated herein by
reference. Other inducible promoters include plant-derived
promoters, such as the promoters in the systemic acquired
resistance pathway, for example, PR promoters. It is noted that
where inducible promoters are discussed herein, activatable
promoters and expression cassettes can be used in a similar fashion
in certain embodiments of the invention.
[0028] A "marker gene" is a gene encoding a selectable or
screenable trait.
[0029] A "medical food" includes a composition that is eaten or
drunk by a host and has a therapeutic effect on the host. A medical
food includes, for example, a sprouted seedling of the present
invention or plant matter derived thereof. A medical food may be
ingested alone or may be administered in combination with a
pharmaceutical composition well known in the medical arts. A
medical food also includes the equivalent feedstuff for non-human
animals.
[0030] "Operably linked" refers to components of a chimeric gene or
an expression cassette that functions as a unit to express a
heterologous protein. For example, a promoter operably linked to a
heterologous DNA, which encodes a protein, promotes the production
of functional mRNA corresponding to the heterologous DNA. A
regulatory DNA sequence is said to be "operably linked to" or
"associated with" a DNA sequence that codes for an RNA or a protein
if the two sequences are situated such that the regulatory DNA
sequence affects expression of the coding DNA sequence.
[0031] "Oral administration" of a pharmaceutically active peptide
or protein means primarily administration by way of the mouth,
preferably by eating, but also intends to include any
administration that provides such peptides or proteins to the
host's stomach or digestive track. In a preferred embodiment, oral
administration results in contact of the pharmaceutically active
protein with the gut mucosa.
[0032] A "pharmaceutically active protein" aids or contributes to
the condition of a host in a positive manner when administered to
the host in a therapeutically effective amount. A pharmaceutically
active protein has healing curative or palliative properties
against a disease and may be administered to ameliorate relieve,
alleviate, reverse or lessen the severity of a disease. A
pharmaceutically active protein also has prophylactic properties
and is used to prevent the onset of a disease or to lessen the
severity of such disease or pathological condition when it does
emerge. Pharmaceutically active proteins include an entire protein
or peptide or pharmaceutically active fragments thereof. It also
includes pharmaceutically active analogs of the protein or peptide
or analogs of fragments of the protein or peptide. The term
pharmaceutically active protein also refers to a plurality of
proteins or peptides that act cooperatively or synergistically to
provide a therapeutic benefit. It is noted that the term
"pharmaceutically active protein" includes proteins that comprise
vaccine antigens, i.e., administration of the protein to a subject
elicits a partially or fully protective immune response in the
host. In certain embodiments of the invention the immune response
protects the subject against an infectious agent, e.g., a virus,
bacterial, fungal, or protozoal pathogen. Examples of vaccine
antigens include hepatitis B surface antigen (HBsAg), E. coli
heat-labile enterotoxin, rabies virus glycoprotein, and Norwalk
virus capsid protein. In other embodiments of the invention the
immune response protects the subject against a non-infectious
condition or disease or lessens the severity of at least one sign
or symptom of the condition or disease. Diseases of interest in
this regard include, but are not limited to, cancer and auto-immune
diseases. The term "pharmaceutically active protein" includes
proteins that partially or fully tolerize a subject to exposure to
an allergen that would otherwise elicit an allergic or anaphylactic
response. A "pharmaceutically active nucleic acid" is a nucleic
acid that encodes a pharmaceutically active protein or is
pharmaceutically active in its own right, e.g., it has one or more
pharmaceutical activities such as those described for
pharmaceutically active proteins. For example, the nucleic acid may
be one or more strands of an RNA interference (RNAi) agent. Such
agents include short interfering RNAs (siRNAs), or short hairpin
RNAs (shRNAs), or precursor of an siRNA or microRNA-like RNA,
targeted to a target transcript, e.g., a transcript of an
infectious agent or an endogenous disease-related transcript of a
subject. An RNA interference
[0033] A "promoter," as used herein, is a DNA sequence that
initiates transcription of an associated DNA sequence. The promoter
region may also include elements that act as regulators of gene
expression such as activators, enhancers, and/or repressors.
[0034] "Regulatory elements" refer to sequences involved in
conferring the expression of a nucleotide sequence. Regulatory
elements include 5' regulatory sequences such as promoters that can
be linked to the nucleotide sequence of interest, 3' sequences such
as 3' regulatory sequences or termination signals. Regulatory
elements also typically encompass sequences required for proper
translation of the nucleotide sequence.
[0035] "Small molecules" are typically less than about one
kilodalton and are biological, organic, or even inorganic compounds
(e.g., cisplatin). Examples of such small molecules include
nutrients such as sugars and sugar-derivatives (including phosphate
derivatives), hormones (such as the phytohormones gibberellic or
absisic acid), and synthetic small molecules.
[0036] "Specifically regulatable" refers to the ability of a small
molecule to preferentially affect transcription from one promoter
or group of promoters, as opposed to non-specific effects, such as
enhancement or reduction of global transcription within a cell.
[0037] A "sprouted seedling" or "sprout" is a young shoot from a
seed or a root, preferably a recently germinated seed. Preferably,
the sprouted seedlings of the invention are edible sprouted
seedlings or sprouts (e.g., alfalfa sprouts, mung bean sprouts,
radish sprouts, wheat sprouts, mustard sprouts, spinach sprouts,
carrot sprouts, beet sprouts, onion sprouts, garlic sprouts, celery
sprouts, rhubarb sprouts, a leaf such as cabbage sprouts, or
lettuce sprouts, watercress or cress sprouts, herb sprouts such as
parsley or clover sprouts, cauliflower sprouts, broccoli sprouts,
soybean sprouts, lentil sprouts, edible flower sprouts such as
sunflower sprouts, etc.). According to the present invention, the
sprouted seedling may have developed to the two-leaf stage.
Generally, the sprouts of the invention are two to fourteen days
old.
[0038] "Substantially isolated" is used in several contexts and
typically refers to the at least partial purification of a protein
or polypeptide away from unrelated or contaminating components (for
example, plant structural and metabolic proteins). Methods for
isolating and purifying proteins or polypeptides are well known in
the art.
[0039] "Transformation" refers to introduction of a nucleic acid
into a cell, particularly the stable integration of a DNA molecule
into the genome of an organism of interest.
DESCRIPTION OF THE DRAWING
[0040] FIG. 1 is a schematic representation of different strategies
for foreign gene expression using plant virus-based vectors.
[0041] FIG. 2 is a schematic representation of AIMV and TMV
genomes.
[0042] FIG. 3 is a picture of a Western blot of expression of
recombinant GFP in Necotiana benthamiana plants inoculated with
Av/A4 and Av A4GFP.
[0043] FIG. 4 is a picture of a Western blot of human growth
hormone (hGH) production in N. benthamiana plants infected with in
vitro transcripts of GH.
[0044] FIG. 5 is a schematic representation of transformation
constructs for expression of recombinant proteins in Brassica
juncea.
[0045] FIG. 6 is a picture of an immunoblot of transgenic Brassica
juncea expressing human growth hormone under control of the HSP18.2
promoter.
[0046] Figure depicts a schematic of a target gene engineered into
agrobacterial expression system. FIG. 7A: IV=any plant promoter,
artificial promoter, or other promoter that functions in plant
cells, e.g., a promoter of a plant virus such as cauliflower mosaic
virus; FIG. 7B depicts a schematic of a GUS gene; FIG. 7C depicts a
plant virus vector or replicon containing target sequences
engineered into the system; FIG. 7D depicts a plant virus or
replicon containing GFP.
[0047] FIG. 8 demonstrates GUS staining after agro infiltration.
FIG. 9A demonstrates staining of Mung bean sprout; FIG. 8B
demonstrates staining of Fenugreek sprouts.
[0048] FIG. 9 demonstrates GUS staining after agro-infiltration of
Brassica sprouts. FIG. 9A demonstrates staining results; FIG. 9B is
a table of the sprouts tested in 9A.
[0049] FIG. 10 demonstrates GFP expression in N. benthamiana over
time after infiltration with pBI121/D4-GFPC3.
[0050] FIG. 11 demonstrates western blot analysis of hGH expression
in plants as a result of infiltration with Agrobacterium containing
a virus vector containing a sequence encoding hGH. Lanes: Lane 1:
ladder; Lane 2: 50 ng hGH; Lane 3: Plant sample infiltrated with
pBI121/D4-HGH 6 dpi 1:2 dilution; Lane 4: Plant sample infiltrated
with pBI121/D4-HGH 6 dpi 1:10 dilutio; Lane 5: Plant sample
infiltrated with pBI121/D4-HGH 6 dpi 1:50 dilution; Lane 6: Plant
sample infiltrated with pBI121/D4-HGH 6 dpi 1:100 dilution; Lane 7:
Plant sample from Healthy plant; Lane 8: Plant sample from
pBI121-infiltrate leaves; Lane 9: Plant sample from D4-HGH infected
plant 13 dpi; Lane 10: Sample from D4-HGH infected clonal root
line. For plant samples: one leaf disc (.about.5 mg tissue) is
ground in 100 uL Bradley buffer with Laemmli loading buffer. 10 ul
is loaded per lane. Therefore, for lanes 3-6, this primary sample
was diluted.
[0051] FIG. 12 demonstrates expression of IA-2ic protein in in
Nicotiana benthamiana plants grown in hydroponics. Lanes: 1. IA-2ic
standard; 2. Magic Marker; 3. Soil-grown plants injected with
agrobacteria; 4, 5. Hydroponics-grown plants 4 days after
infiltration; 6, 7. Hydroponics-grown plants 6 days after
infiltration.
DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS
[0052] The present invention provides systems and methods of
producing pharmaceutical peptides and proteins in edible sprouted
seedlings. The present invention further provides edible sprouted
seedlings as a biomass containing a pharmaceutical peptide or
protein. In certain preferred embodiments, the biomass is provided
directly for consumption. In other preferred embodiments, the
biomass is processed prior to consumption, for example, by
homogenizing, crushing, drying, or extracting. In yet other
preferred embodiments, the pharmaceutical protein is purified from
the biomass and formulated into a pharmaceutical composition.
[0053] In certain preferred embodiments, genetically engineered
seeds or embryos that contain a transgene encoding a pharmaceutical
peptide or protein of interest are grown to the sprouted seedling
stage in a contained, regulatable environment. In preferred
embodiments, the contained, regulatable environment is a housing
unit or room in which the seeds can be grown indoors. All
environmental factors of the contained, regulatable environment may
be controlled. Since sprouts do not require light to grow, and
lighting can be expensive, in one particularly preferred
embodiment, the genetically engineered seeds or embryos are grown
to the sprouted seedling stage indoors in the absence of light.
[0054] Other environmental factors that can be regulated in the
contained, regulatable environment of the present invention include
temperature, humidity, water, nutrients, gas (e.g., O.sub.2 or
CO.sub.2 content or air circulation), chemicals (small molecules
such as sugars and sugar derivatives or hormones such as such as
the phytohormones gibberellic or absisic acid, etc.) and the
like.
[0055] According to the present invention, expression of the
transgene encoding the pharmaceutical protein is preferably
controlled by an exogenously inducible promoter. Exogenously
inducible promoters are caused to increase or decrease expression
of a transgene in response to an external, rather than an internal
stimulus. A number of these environmental factors can act as
inducers for expression of the transgenes carried by the expression
cassettes of the genetically engineered sprouts. In certain
preferred embodiments, the promoter is a heat-inducible promoter,
such as a heat-shock promoter. For example, using as heat-shock
promoter the temperature of the contained environment may simply be
raised to induce expression of the transgene. Other promoters
include light inducible promoters. Light-inducible promoters can be
maintained as constitutive promoters if the light in the contained
regulatable environment is always on. Alternatively, expression of
the transgene can be turned on at a particular time during
development by simply turning on the light. In yet other preferred
embodiments, a chemically inducible promoter is used to induce
expression of the transgene. According to these embodiments, the
chemical could simply be misted or sprayed onto the seed, embryo,
or seedling to induce expression of the transgene. Spraying and
misting can be precisely controlled and directed onto the target
seed, embryo, or seedling to which it is intended. The contained
environment is devoid of wind or air currents, which could disperse
the chemical away from the intended target, so that the chemical
stays on the target for which it was intended.
[0056] According to the present invention, the time expression is
induced is preferably selected to maximize expression of the
pharmaceutical protein in the sprouted seedling by the time of
harvest. Inducing expression in an embryo at a particular stage of
growth, for example, inducing expression in an embryo at a
particular number of days after germination, may result in maximum
synthesis of the pharmaceutical protein at the time of harvest. For
example, inducing expression from the promoter 4 days after
germination may result in more protein synthesis than inducing
expression from the promoter after 3 days or after 5 days. Those
skilled in the art will appreciate that maximizing expression can
be achieved by routine experimentation. In preferred embodiments,
the sprouted seedlings are harvested at about 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, or 12 days after germination.
[0057] In cases where the expression vector has a constitutive
promoter instead of an inducible promoter, the sprouted seedling
may be harvested at a certain time after transformation of the
sprouted seedling. For example, if a sprouted seedling were virally
transformed at an early stage of development, for example, at the
embryo stage, the sprouted seedlings may be harvested at a time
when expression is at its maximum post-transformation, e.g., at
about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days
post-transformation. It could also be that sprouts develop one,
two, three or more months post-transformation, depending on the
germination of the seed.
[0058] Generally, once expression of the pharmaceutical protein
begins, the seeds, embryos, or sprouted seedlings are allowed to
grow until sufficient levels of the pharmaceutical protein are
expressed. In certain preferred embodiments, sufficient levels are
levels that would provide a therapeutic benefit to a patient if the
harvested biomass were eaten raw. Alternatively, sufficient levels
are levels from which the pharmaceutical protein can be
concentrated or purified from the biomass and formulated into a
pharmaceutical composition that provides a therapeutic benefit to a
patient upon administration. Typically, the pharmaceutical protein
is not a protein expressed in the sprouted seedling in nature. At
any rate, the pharmaceutical protein is preferably expressed at
concentrations above that which would be present in the sprouted
seedling in nature.
[0059] In preferred embodiments, once expression of the
pharmaceutical protein is induced, growth is allowed to continue
until the sprouted seedling stage, at which time the sprouted
seedlings are harvested. In a particularly preferred embodiment,
the sprouted seedlings are harvested live. Harvesting live sprouted
seedlings has several advantages including minimal effort and
breakage. The spouted seedlings of the present invention are
preferably grown hydroponically making harvesting a simple matter
of lifting the sprouted seedling from its hydroponic solution. No
soil is required for the growth of the sprouted seedlings of the
invention, but may be provided if deemed necessary or desirable by
the skilled artisan. Because sprouts can be grown without soil, no
cleansing of sprouted seedling material is required at the time of
harvest. Being able to harvest the sprouted seedling directly from
its hydroponic environment without washing or scrubbing minimizes
breakage of the harvested material. Breakage and wilting of plants
induces apoptosis. During apoptosis, certain proteolytic enzymes
become active, which can degrade the pharmaceutical protein
expressed in the sprouted seedling, resulting in decreased
therapeutic activity of the protein. Apoptosis-induced proteolysis
significantly decreases the yield of protein from mature plants.
Using the methods of the present invention, apoptosis is preferably
(i.e., apoptosis is avoided) never induced because no harvesting
takes place until the moment the proteins are extracted from the
plant.
[0060] For example, live sprouts may be ground, crushed, or blended
to produce a slurry of sprouted seedling biomass, in a buffer
containing protease inhibitors. Preferably the buffer is at about
4.degree. C. In other preferred embodiments, the sprouted seedling
biomass is air-dried, spray dried, frozen, or freeze-dried. As in
mature plants, some of these methods, such as air-drying, may
result in a loss of activity of the pharmaceutical protein.
However, because sprouted seedlings are very small and have a large
surface area to volume ratio, this is much less likely to occur.
Those skilled in the art will appreciate that many techniques for
harvesting the biomass that minimize proteolysis of the
pharmaceutical protein are available and could be applied to the
present invention.
[0061] The sprouted seedlings are preferably edible. In
particularly preferred embodiments, sprouted seedlings expressing
sufficient levels of pharmaceutical proteins are consumed live so
that absolutely no harvesting occurs before the sprouted seedlings
are consumed. In this way, it is guaranteed that there is no
harvest-induced proteolytic breakdown of the pharmaceutical protein
before administration of the pharmaceutical protein to a patient in
need of treatment. For example, sprouted seedlings that are ready
to be consumed can be delivered directly to a patient.
Alternatively, genetically engineered seeds or embryos are
delivered to a patient in need of treatment and grown to the
sprouted seedling stage by the patient. In one preferred
embodiment, a supply of genetically engineered sprouted seedlings
are provided to a patient, or to a doctor who will be treating
patients, so that a continual stock of sprouted seedlings
expressing certain desirable pharmaceutical proteins may be
cultivated. This may be particularly valuable for populations in
developing countries, where expensive pharmaceuticals are not
affordable or deliverable. The ease with which the sprouted
seedlings of the invention can be grown makes the sprouted
seedlings of the present invention particularly desirable for such
developing populations.
[0062] The regulatable nature of the contained environment imparts
advantages to the present invention over growing plants in the
outdoor environment. In general, growing genetically engineered
sprouted seedlings that express pharmaceutical proteins in plants
provides a pharmaceutical product faster (because the plants are
harvested younger) and with less effort, risk, and regulatory
considerations than growing genetically engineered plants. The
contained, regulatable environment used in the present invention
reduces or eliminates the risk of cross-pollinating plants in the
nature.
[0063] For example, a heat inducible promoter could never be used
in the outdoors because the outdoor temperature cannot be
controlled. The promoter would be turned on any time the outdoor
temperature rose above a certain level. Similarly, the promoter
would be turned off every time the outdoor temperature dropped.
Such temperature shifts could occur in a single day, for example,
turning expression on in the daytime and off at night. A heat
inducible promoter, such as those described herein, would not even
be practical for use in a greenhouse, which is susceptible to
climatic shifts to almost the same degree as the outdoors. Growth
of genetically engineered plants in a greenhouse is quite costly.
In contrast, in the present system, every variable can be
controlled so that the maximum amount of expression can be achieved
with every harvest.
[0064] In preferred embodiments, the sprouted seedlings of the
present invention are grown in trays that can be watered, sprayed,
or misted at any time during the development of the sprouted
seedling. For example, the tray may be fitted with one or more
watering, spraying, misting, and draining apparatus that can
deliver and/or remove water, nutrients, chemicals etc. at specific
time and at precise quantities during development of the sprouted
seedling. For example, seeds require sufficient moisture to keep
them damp. Excess moisture drains through holes in the trays into
drains in the floor of the room. Preferably, drainage water is
treated as appropriate for removal of harmful chemicals before
discharge back into the environment.
[0065] Another advantage of the trays of the present system is that
they can be contained within a very small space. Since no light is
required for the sprouted seedlings to grow, the trays containing
seeds, embryos, or sprouted seedlings may be tightly stacked
vertically on top of one another, providing a large quantity of
biomass per unit floor space in a housing facility constructed
specifically for these purposes. In addition, the stacks of trays
can be arranged in horizontal rows within the housing unit. Once
the seedlings have grown to a stage appropriate for harvest (about
two to fourteen days) the individual seedling trays are moved into
a processing facility, either manually or by automatic means, such
as a conveyor belt.
[0066] The system of the present invention is unique in that it
provides a sprouted seedling biomass, which is a source of a
pharmaceutically active protein. Whether consumed directly or
processed into the form of a pharmaceutical composition, because
the sprouted seedlings are grown in a contained, regulatable
environment, the sprouted seedling biomass and/or pharmaceutical
composition derived from the biomass can be provided to a consumer
at low cost. In addition, the fact that the conditions for growth
of the sprouted seedlings can be controlled makes the quality and
purity of the product consistent. The contained, regulatable
environment of the invention also obviates many safety regulations
of the EPA that can prevent scientists from growing genetically
engineered agricultural products out of doors.
Pharmaceuticals
[0067] The pharmaceutical proteins of the present invention, which
are expressed in sprouted seedlings, include any pharmaceutical
protein of interest, either prokaryotic or eukaryotic. Generally,
the pharmaceutical proteins of interest include, but are not
limited to, hormones (insulin, thyroid hormone, catecholamines,
gonadotrophines, trophic hormones, prolactin, oxytocin, dopamine,
bovine somatotropin, leptins and the like), growth hormones (e.g.,
human grown hormone), growth factors (e.g., epidermal growth
factor, nerve growth factor, insulin-like growth factor and the
like), growth factor receptors, cytokines and immune system
proteins (e.g., interleukins, colony stimulating factor (CSF),
granulocyte colony stimulating factor (G-CSF),
granulocyte-macrophage colony stimulating factor (GM-CSF),
erythropoietin, tumor necrosis factor (TNF), interfersons,
integrins, addressins, seletins, homing receptors, T cell
receptors, immunoglobulins, soluble major histocompatibility
complex antigens, immunologically active antigens such as
bacterial, parasitic, or viral antigens or allergens),
autoantigens, antibodies), enzymes (tissue plasminogen activator,
streptokinase, cholesterol biosynthestic or degradative,
steriodogenic enzymes, kinases, phosphodiesterases, methylases,
de-methylases, dehydrogenases, cellulases, proteases, lipases,
phospholipases, aromatases, cytochromes, adenylate or guanylaste
cyclases, neuramidases and the like), receptors (steroid hormone
receptors, peptide receptors), binding proteins (sterpod binding
proteins, growth hormone or growth factor binding proteins and the
like), transcription and translation factors, oncoprotiens or
proto-oncoprotiens (e.g., cell cycle proteins), muscle proteins
(myosin or tropomyosin and the like), myeloproteins, neuroactive
proteins, tumor growth suppressing proteins (angiostatin or
endostatin, both which inhibit angiogenesis), anti-sepsis proteins
(bectericidal permeability-increasing protein), structural proteins
(such as collagen, fibroin, fibrinogen, elastin, tubulin, actin,
and myosin), blood proteins (thrombin, serum albumin, Factor VII,
Factor VIII, insulin, Factor IX, Factor X, tissue plasminogen
activator, Protein C, von Wilebrand factor, antithrombin III,
glucocerebrosidase, erythropoietin granulocyte colony stimulating
factor (GCSF) or modified Factor VIII, anticoagulants such as
huridin) and the like.
[0068] The present invention also provides pharmaceutical proteins
for veterinary use, such as vaccines and growth hormones, which may
be produced by the sprouted seedlings of the invention.
Suitable Plants
[0069] Those skilled in the art will appreciate that the plants
that may be transformed in the present invention include any
transformable plant of any stage of development (e.g., adult
plants, seeds, seedlings etc.) that is edible as a seedling. In
certain preferred embodiments, the plants of the invention may be
plants of the Brassica or Arabidopsis species. Some suitable plants
that are amendable to transformation and are edible as sprouted
seedlings include alfalfa, mung bean, radish, wheat, mustard,
spinach, carrot, beet, onion, garlic, celery, rhubarb, a leafy
plant such as cabbage or lettuce, watercress or cress, herbs such
as parsley, mint, or clovers, cauliflower, broccoli, soybean,
lentils, edible flowers such as the sunflower etc.
Generating Transformed Sprouts
[0070] A variety of methods can be used to transform plant cells
and produce genetically engineered sprouted seedlings. Two
available methods for the transformation of plants that require
that transgenic plant cell lines be generated in vitro, followed by
regeneration of the cell lines into whole plants include
Agrobacterium tumefaciens mediated gene transfer and
microprojectile bombardment or electroporation. Viral
transformation is a more rapid and less costly methods of
transforming embryos and sprouted seedlings that can be harvested
without an experimental or generational lag prior to obtaining the
desired product. For any of these techniques, the skilled artisan
would appreciate how to adjust and optimize transformation
protocols that have traditionally been used for plants, seeds,
embryos, or spouted seedlings.
[0071] Agrobacterium Transformation Expression Cassettes.
Agrobacterium is a representative genus of the gram-negative family
Rhizobiaceae. This species is responsible for plant tumors such as
crown gall and hairy root disease. In dedifferentiated plant
tissue, which is characteristic of tumors, amino acid derivatives
known as opines are produced by the Agrobacterium and catabolized
by the plant. The bacterial genes responsible for expression of
opines are a convenient source of control elements for chimeric
expression cassettes. According to the present invention, the
Agrobacterium transformation system may be used to generate edible
sprouted seedlings, which are merely harvested earlier than the
mature plants. Agrobacterium transformation methods can easily be
applied to regenerate sprouted seedlings expressing pharmaceutical
proteins.
[0072] hi general, transforming plants involves the transformation
of plant cells grown in tissue culture by co-cultivation with an
Agrobacterium tumefaciens carrying a plant/bacterial vector. The
vector contains a gene encoding a pharmaceutical protein. The
Agrobacterium transfers the vector to the plant host cell and is
then eliminated using antibiotic treatment. Transformed plant cells
expressing the pharmaceutical protein are selected, differentiated,
and finally regenerated into complete plantlets (Hellens at al.,
Plant Molecular Biology (2000) 42(819-832); Pilon-Smits et al,
Plant Physiolog. (January 1999) 119(1):123-132; Barfield and Pua
Plant Cell Reports (1991)10(6/7):308-314); Riva et al., Journal of
Biotechnology (Dec. 15, 1998) 1(3), each incorporated by reference
herein.
[0073] Expression vectors for use in the present invention include
a gene (or expression cassette) encoding a pharmaceutical protein
designed for operation in plants, with companion sequences upstream
and downstream of the expression cassette. The companion sequences
are generally of plasmid or viral origin and provide necessary
characteristics to the vector to transfer DNA from bacteria to the
desired plant host.
[0074] The basic bacterial/plant vector construct preferably
provides a broad host range prokaryote replication origin, a
prokaryote selectable marker. Suitable prokaryotic selectable
markers include resistance toward antibiotics such as ampicillin or
tetracycline. Other DNA sequences encoding additional functions
that are well known in the art may also be present in the
vector.
[0075] Agrobacterium T-DNA sequences are required for Agrobacterium
mediated transfer of DNA to the plant chromosome. The
tumor-inducing genes of the T-DNA are typically removed and
replaced with sequences encoding the pharmaceutical protein. The
T-DNA border sequences are retained because they initiate
integration of the T-DNA region into the plant genome. If
expression of the pharmaceutical protein is not readily amenable to
detection, the bacterial/plant vector construct will also include a
selectable marker gene suitable for determining if a plant cell has
been transformed, e.g., the nptII kanamycin resistance gene. On the
same or different bacterial/plant vector (Ti plasmid) are Ti
sequences. Ti sequences include the virulence genes, which encode a
set of proteins responsible for the excision, transfer and
integration of the T-DNA into the plant genome (Schell, Science
(1987) 237:1176-1183). Other sequences suitable for permitting
integration of the heterologous sequence into the plant genome may
also include transposon sequences, and the like, for homologous
recombination.
[0076] Certain constructs will include the expression cassette
encoding the protein of interest. One, two, or more expression
cassettes may be used in a given transformation. The recombinant
expression cassette contains, in addition to the pharmaceutical
protein encoding sequence, at least the following elements: a
promoter region, plant 5' untranslated sequences, initiation codon
(depending upon whether or not the expressed gene has its own), and
transcription and translation termination sequences. In addition,
transcription and translation terminators may be included in the
expression cassettes or chimeric genes of the present invention.
Signal secretion sequences that allow processing and translocation
of the protein, as appropriate, may also be included in the
expression cassette. A variety of promoters, signal sequences, and
transcription and translation terminators are described, for
example, in Lawton et al., Plant Mol. Biol (1987) 9:315-324 or U.S.
Pat. No. 5,888,789, incorporated herein by reference. In addition,
structural genes for antibiotic resistance are commonly utilized as
a selection factor (Fraley et al. Proc. Natl. Acad. Sci., USA
(1983) 80:4803-4807), incorporated herein by reference. Unique
restriction enzyme sites at the 5' and 3' ends of the cassette
allow for easy insertion into a pre-existing vector. Other binary
vector systems for Agrobacterium-mediated transformation, carrying
at least one T-DNA border sequence are described in PCT/EP99/07414,
incorporated herein by reference. Further discussion of
Agrobacterium-mediated transformation is found in Gelvin, S. B.,
"Agrobacterium-Mediated Plant Transformation: the Biology behind
the "Gene-Jockeying" Tool", Microbiology and Molecular Biology
Reviews, 67(1): 16-37 (2003), incorporated herein by reference, and
references therein, all of which are incorporated herein by
reference; Lorene A, Verpoorte R., Gene transfer and expression in
plants. Methods Mol Biol. (2004) 267:329-50, incorporated herein by
reference. In certain embodiments of the invention bacteria other
than Agrobacteria are used to introduce a nucleic acid sequence
into a plant. See, e.g., Broothaerts W, et al., Gene transfer to
plants by diverse species of bacteria, Nature (2005),
433(7026):629-633, which is incorporated herein by reference.
[0077] Regeneration. Seeds of transformed plants are harvested,
dried, cleaned, and tested for viability and for the presence and
expression of a desired gene product. Once this has been
determined, seed stock is stored under appropriate conditions of
temperature, humidity, sanitation, and security to be used when
necessary. Whole plants are then regenerated from cultured
protoplasts, e.g., as described in Evans et al., Handbook of Plant
Cell Cultures, Vol. 1:MacMillan Publishing Co. New York, 1983); and
Vasil I. R. (ed.), Cell Culture and Somatic Cell Genetics of
Plants, Acad. Press, Orlando, Vol. I, 1984, and Vol. III, 1986,
incorporated herein by reference. In preferred embodiments, the
plants are regenerated only to the sprouted seedling stage. In
other preferred embodiments, whole plants are regenerated to
produce seed stocks and sprouted seedlings are generated from the
seeds of the seed stock.
[0078] All plants from which protoplasts can be isolated and
cultured to give whole, regenerated plants can be transformed by
the present invention so that whole plants are recovered that
contain the transferred gene. It is known that practically all
plants can be regenerated from cultured cells or tissues,
including, but not limited to, all major species of plants that
produce edible sprouts. Some suitable plants include alfalfa, mung
bean, radish, wheat, mustard, spinach, carrot, beet, onion, garlic,
celery, rhubarb, a leafy plant such as cabbage or lettuce,
watercress or cress, herbs such as parsley, mint, or clovers,
cauliflower, broccoli, soybean, lentils, edible flowers such as the
sunflower etc.
[0079] Means for regeneration vary from one species of plants to
the next. However, those skilled in the art will appreciate that
generally a suspension of transformed protoplants containing copies
of the heterologous gene is first provided. Callus tissue is formed
and shoots may be induced from callus and subsequently rooted.
Alternatively, embryo formation can be induced from the protoplast
suspension. These embryos germinate as natural embryos to form
plants. Steeping the seed in water or spraying the seed with water
to increase the moisture content of the seed to between 35-45%
initiates germination. For germination to proceed, the seeds are
typically maintained in air saturated with water under controlled
temperature and airflow conditions. The culture media will
generally contain various amino acids and hormones, such as auxin
and cytokinins. It is also advantageous to add glutamic acid and
proline to the medium, especially for such species as alfalfa.
Shoots and roots normally develop simultaneously. Efficient
regeneration will depend on the medium, the genotype, and the
history of the culture. If these three variables are controlled,
then regeneration is fully reproducible and repeatable.
[0080] The mature plants, grown from the transformed plant cells,
are selfed and non-segregating, homozygous transgenic plants are
identified. The inbred plant produces seeds containing the chimeric
gene of the present invention. These seeds can be germinated and
grown to the sprouted seedling stage to produce the pharmaceutical
protein or polypeptide of interest.
[0081] In related embodiments, the seeds of the present invention
are formed into seed products and sold with instructions on how to
grow the seedlings to the appropriate sprouted seedling stage for
administration or harvesting into a pharmaceutical composition. In
other related embodiments, hybrids or novel varieties embodying the
desired traits are developed from the inbred plants of the
invention.
[0082] Direct Integration. Direct integration of DNA fragments into
the genome of plant cells by microprojectile bombardment or
electroporation may also be used in the present invention (see,
e.g., Kikkert, J. R. Humiston et al., In Vitro Cellular &
Developmental Biology. Plant: Journal of the Tissue Culture
Association. (January/February 1999) 35 (1):43-50; Bates, G. W.
Florida State University, Tallahassee, Fla. Molecular Biotechnology
(October 1994) 2(2):135-145). More particularly, vectors containing
a chimeric gene of the present invention can be introduced into
plant cells by a variety of techniques. As described above, the
vectors may include selectable markers for use in plant cells. The
vectors may also include sequences that allow their selection and
propagation in a secondary host, such as sequences containing an
origin of replication and selectable marker. Typically, secondary
hosts include bacteria and yeast. In one preferred embodiment, the
secondary host is Escherichia coli, the origin of replication is a
colE1-type origin of replication, and the selectable marker is a
gene encoding ampicillin resistance. Such sequences are well known
in the art and are commercially available (e.g., Clontech, Palo
Alto, Calif. or Stratagene, La Jolla, Calif.).
[0083] The vectors of the present invention may also be modified to
intermediate plant transformation plasmids that contain a region of
homology to an Agrobacterium tumefaciens vector, a T-DNA border
region from Agrobacterium tumefaciens, and chimeric genes or
expression cassettes described above. Further vectors may include a
disarmed plant tumor inducing plasmid of Agrobacterium
tumefaciens.
[0084] According to the present embodiment, direct transformation
of the vectors invention involves microinjecting the vectors
directly into plant cells by the use of micropipettes to
mechanically transfer the recombinant DNA (see, e.g., Crossway,
Mol. Gen. Genet., 202:179-185, 1985, incorporated herein by
reference). The genetic material may also be transferred into the
plant cell by using polyethylene glycols (see, e.g., Krens et al.,
Nature (1982) 296:72-74). Another method of introducing nucleic
acid segments is high velocity ballistic penetration by small
particles with the nucleic acid either within the matrix of small
beads or particles, or on the surface (see, e.g., Klein et al.,
Nature (1987) 327:70-73; Knudsen and Muller Planta (1991)
185:330-336)). Yet another method of introduction is fusion of
protoplasts with other entities, either minicells, cells,
lysosomes, or other fusible lipid-surfaced bodies (see, e.g.,
Fraley et al., Proc. Natl. Acad. Sci. USA (1982) 79:1859-1863).
Vectors of the invention may also be introduced into plant cells by
electroporation (see, e.g., Fromm et al. Proc. Natl. Acad. Sci. USA
(1985) 82:5824). According to this technique, plant protoplasts are
electroporated in the presence of plasmids containing the gene
construct. Electrical impulses of high field strength reversibly
permeabilize biomembranes allowing the introduction of the pasmids.
Electroporated plant protoplasts reform the cell wall divide and
form plant callus, which can be regenerated to form the sprouted
seedlings of the invention. Those skilled in the art would
appreciate how to utilize these methods to transform plants cells
that can be used to generate edible sprouted seedlings.
[0085] Viral Transformation. Expression and inexpensive recovery of
peptides with adequate biological activity is important for
different applications including development of subunit vaccines.
Some applications, however, require full-length, biologically
active proteins. Similarly to conventional expression systems,
plant virus vectors can also be used to produce full-length
proteins, including enzymes, blood component substitutes, and
antibodies. According to the present invention, plant virus vectors
are used to infect and produce foreign protein in seeds, embryos,
sprouted seedlings. In this regard infection includes any method of
introducing a viral genome, or portion thereof, into a cell,
including, but not limited to, the natural infectious process of a
virus, abrasion, inoculation, etc. The term includes introducing a
genomic RNA transcript, or a cDNA copy thereof, into a cell. The
viral genome need not be a complete genome but will typically
contain sufficient sequences to allow replication. The genome may
encode a viral replicase and may contain any cis-acting nucleic
acid elements necessary for replication. Expression of high levels
of foreign genes encoding short peptides as well as large complex
proteins by tobamoviral vectors is described, for example, by
McCormick et al. (Proc. Natl. Acad. Sci. USA (1999) 96:703-708;
Kumagai et al. (Gene (2000) 245:169-174 and Verch et al. (J.
Immunol. Methods (1998) 220, 69-75, each incorporated herein by
reference). Thus, plant virus vectors have a demonstrated ability
to express short peptides as well as large complex proteins.
[0086] In preferred embodiments, sprouts, which express
pharmaceutical proteins such as insulin, GAD, and IA-2 associated
with type 1 diabetes, are generated utilizing a host/virus system.
Sprouts produced by viral infection provide a source of protein
that has already been demonstrated to be safe. For example, sprouts
are free of contamination with animal pathogens. Unlike, for
example, tobacco, proteins from an edible sprout could at least in
theory be used in oral applications without purification, thus
significantly reducing costs. In addition, a virus/sprout system
also offers a much simpler, less expensive route for scale-up and
manufacturing, since the trangenes are introduced into the virus,
which can be grown up to a commercial scale within a few days. In
contrast, transgenic plants can require up to 5-7 years before
sufficient seeds or plant material are available for large-scale
trials or commercialization.
[0087] According to the present invention, plant RNA viruses have
certain advantages, which make them attractive as vectors for
foreign protein expression. The molecular biology and pathology of
a number of plant RNA viruses are well characterized and there is
considerable knowledge of virus biology, genetics, and regulatory
sequences. Most plant RNA viruses have small genomes and infectious
cDNA clones are available to facilitate genetic manipulation. Once
the infectious virus material enters the susceptible host cell, it
replicates to high levels and spreads rapidly throughout the entire
sprouted seedling (one to ten days post inoculation). Virus
particles are easily and economically recovered from infected
sprouted seedling tissue. Viruses have a wide host range, enabling
the use of a single construct for infection of several susceptible
species. These characteristics are easily transferable to
sprouts.
[0088] FIG. 1 illustrates several different strategies for
expressing foreign genes using plant viruses. Foreign sequences can
be expressed by replacing one of the viral genes with desired
sequence, by inserting foreign sequences into the virus genome at
an appropriate position, or by fusing foreign peptides to the
structural proteins of a virus. Moreover, any of these approaches
can be combined to express foreign sequences by
trans-complementation of vital functions of a virus. A number of
different strategies exist as tools to express foreign sequences in
virus-infected plants using tobacco mosaic virus (TMV), alfalfa
mosaic virus (A1MV), and chimeras thereof.
[0089] The genome of AIMV is a representative of the Bromoviridae
family of viruses and consists of three genomic RNAs (RNAs1-3) and
subgenomic RNA (RNA4) (FIG. 2). Genomic RNAs1 and 2 encode virus
replicase proteins P1 and 2, respectively. Genomic RNA3 encodes the
cell-to-cell movement protein P3 and the coat protein (CP). The CP
is translated from subgenomic RNA4, which is synthesized from
genomic RNA3, and is required to start the infection. Studies have
demonstrated the involvement of the CP in multiple functions,
including genome activation, replication, RNA stability, symptom
formation, and RNA encapsidation (see e.g., Bol et al., Virology
(1971) 46: 73-85; Van Der Vossen et al., Virology (1994) 202:
891-903; Yusibov et al., Virology 208: 405-407; Yusibov et al.,
Virology (1998) 242: 1-5; Bol et al., (Review, 100 refs.). J. Gen.
Virol. (1999) 80: 1089-1102; De Graaff, Virology (1995) 208:
583-589; Jaspars et al., Adv. Virus Res (1974). 19, 37-149;
Loesch-Fries, Virology (1985)146: 177-187; Neeleman et al.,
Virology (1991) 181: 687-693; Neeleman et al., Virology (1993) 196:
883-887; Van Der Kuyl et al., Virology (1991) 183: 731-738; Van Der
Kuyl et al., Virology (1991) 185: 496-499).
[0090] Encapsidation of viral particles is essential for long
distance movement of virus from inoculated to un-inoculated parts
of the seed, embryo, or sprouted seedling and for systemic
infection, According to the present invention, inoculation can
occur at any stage of plant development. In embryos and sprouts,
spread of the inoculated virus should be very rapid. Virions of
AIMV are encapsidated by a unique CP (24 kD), forming more than one
type of particle. The size (30- to 60-nm in length and 18 nm in
diameter) and shape (spherical, ellipsoidal, or bacilliform) of the
particle depends on the size of the encapsidated RNA. Upon
assembly, the N-terminus of the AIMV CP is thought to be located on
the surface of the virus particles and does not appear to interfere
with virus assembly (Bol et al., Virology (1971) 6: 73-85).
Additionally, the AIMV CP with an additional 38-amino acid peptide
at its N-terminus forms particles in vitro and retains biological
activity (Yusibov et al., J. Gen. Virol. (1995) 77: 567-573).
[0091] A1MV has a wide host range, which includes a number of
agriculturally valuable crop plants, including plant seeds,
embryos, and sprouts. Together, these characteristics make the AIMV
CP an excellent candidate as a carrier molecule and A1MV an
attractive candidate vector for the expression of foreign sequences
in the plant at the sprout stage of development. Moreover, upon
expression from a heterologous vector such as TMV, the A1MV CP
encapsidates TMV genome without interfering with virus infectivity
(Yusibov et al., Proc. Natl. Acad. Sci. USA (1997) 94: 5784-5788,
incorporated herein by reference). This allows the use of TMV as a
carrier virus for AIMV CP fused to foreign sequences.
[0092] TMV, the prototype of the tobamoviruses, has a genome
consisting of a single plus-sense RNA encapsidated with a 17.0 kD
CP, which results in rod-shaped particles (300 nm in length) (FIG.
2). The CP is the only structural protein of TMV and is required
for encapsidation and long distance movement of the virus in an
infected host (Saito et al., Virology (1990) 176: 329-336). The 183
and 126 kD proteins are translated from genomic RNA and are
required for virus replication (Ishikawa et al., Nucleic Acids Res.
(1986) 14: 8291-8308). The 30 kD protein is the cell-to-cell
movement protein of virus (Meshi et al., EMBO J. (1987) 6:
2557-2563). Movement and coat proteins are translated from
subgenomic mRNAs (Hunter et al., Nature (1976) 260: 759-760;
Bruening et al., Virology (1976) 71: 498-517; Beachy et al.,
Virology (1976) 73: 498-507, each incorporated herein by
reference).
[0093] Schematic representation of AIMV and TMV genomes are shown
in FIG. 2. RNAs1 and 2 of A1MV encode replicase proteins P1 and P2,
respectively; genomic RNA3 encodes cell-to-cell movement protein P3
and the viral coat protein (CP). The CP is translated from
subgenomic RNA4 synthesized from genomic RNA3. The 126 kD and 183
kD proteins of TMV are required for replication; the 30 kD protein
is the viral cell-to-cell movement protein; and the 17 kD protein
is the CP of virus. The CP and the 30 kD protein are translated
from subgenomic RNAs. Arrows indicate position of subgenomic
promoters.
[0094] Other methods of transforming plant tissues include
transforming the flower of the plant. Transformation of Arabidopsis
thaliana can be achieved by dipping the plant flowers into a
solution of Agrobacterium tumefaciens (Curtis and Nam, Transgenic
Research (August 2001) 10 4:363-371; Qing et al., Molecular
Breeding: New Strategies in Plant Improvement (February 2000).
(1):67-72). Transformed plants are formed in the population of
seeds generated by the "dipped" plants. At a specific point during
flower development, a pore exists in the ovary wall through which
Agrobacterium tumefaciens gains access to the interior of the
ovary. Once inside the ovary, the Agrobacterium tumefaciens
proliferates and transforms individual ovules (Desfeux et al.,
Plant Physiology (July 2000) 123(3):895-904). The transformed
ovules follow the typical pathway of seed formation within the
ovary.
Agrobacterium Mediated Transient Expression
[0095] In additional aspects, the invention is directed to a
combined approach of introducing viral expression vectors in
sprouts via agroinfiltration to generate a transient expression
system. Agrobacterium harboring an expression vector sequence
encoding a target gene of interest. For transient transformation,
non-integrated T-DNA copies remain transiently present in the
nucleons and are transcribed leading to the expression of the
carrying genes (Kapila et al., 1997). Agrobacterium-mediated
transient expression, differently from viral vectors, cannot lead
to the systemic spreading of the expression of the gene of
interest. One advantage of this system is the possibility to clone
genes larger than 2 kb to generate constructs that would be
impossible to obtain with viral vectors (Voinnet et al., 2003).
Furthermore, using such technique, it is possible to transform the
plant with more than one transgene, such that multimeric proteins
(e.g., antibodies subunits of complexed proteins) can be expressed
and assembled. Furthermore, the possibility of co-expression of
multiple transgenes by means of co-infiltration with different
Agrobacterium can be taken advantage of, either by separate
infiltration or using mixed cultures.
[0096] In preferred embodiments, an expression vector comprising
viral genome sequence and further comprising sequence encoding a
pharmaceutically active protein are introduced into Agrobacterium.
Thus, binary vectors allow for selection in Agrobacterium as well
as in cells which have been infiltrated with bacteria. Upon
infiltration, viral DNA is transcribed to yield viral RNA
production, followed by generation of viral proteins. Furthermore,
production of viral proteins and viral RNA yields rapid production
of multiple copies of RNA encoding the pharmaceutically active
protein of interest. Such production results in rapid protein
production of the target of interest in a relatively short period
of time. Thus, a highly efficient system for protein production can
be generated.
[0097] The agro-infiltration technique utilizing viral expression
vectors can be used to produce limited quantity of protein of
interest in order to verify the expression levels before deciding
if it is worth generating transgenic plants. Alternatively, the
agro-infiltration technique utilizing viral expression vectors is
useful for rapid generation of plants capable of producing huge
amounts of protein as a primary production platform. Thus, this
transient expression system can be used on industrial scale.
[0098] Further provided are any of a variety of different
Agrobacterial plasmids, binary plasmids, or derivatives thereof
such as pBIV, pBI1221, pGreen, etc., which can be used in these and
other aspects of the invention. Numerous suitable vectors are known
in the art and can be directed and/or modified according to methods
known in the art, or those described herein so as to utilize in the
methods described provided herein.
Seeds
[0099] Still another aspect of the invention embodies seeds which
can be generated and/or utilized for the methods described herein.
Seeds transgenic for any gene of interest can be sprouted and
chemically induced for production. A gene of interest is also
referred to herein as a "target gene". Seeds capable of expressing
any gene of interest can be sprouted and induced through: i) virus
infection, ii) agroinfiltration, or iii) bacteria that contain
virus genome. Seeds capable of expressing a transgene for heavy or
light chain of any monoclonal antibody can be sprouted and induced
for production of full-length molecule through: i) virus infection,
ii) agroinfiltration, or iii) inoculation with bacteria that
contain virus genome. Seeds capable of expressing a transgene for
one or more components of a complex molecule comprising multiple
components such as sIgA can be sprouted and used for producing a
fully functional molecule through: i) virus infection, ii)
agroinfiltration, or iii) inoculation with bacteria that contain
virus genome. Seeds from healthy non-transgenic plants can be
sprouted and used for producing target sequences through: i) virus
infection, ii) agroinfiltration, or iii) inoculation with bacteria
that contain a virus genome.
Administration and Pharmaceutical Compositions
[0100] The present invention provides a sprouted seedling
expressing a pharmaceutically active protein that maintains its
pharmaceutical activity when administered to a host in need
thereof. Preferred hosts include vertebrates, preferably mammals,
more preferably human. According to the present invention, the
hosts include veterinary hosts such as bovines, ovines, canines,
felines, etc. In preferred embodiments, the edible sprout is
administered orally to a host in a therapeutically effective
amount. In other preferred embodiments, the pharmaceutically active
protein is provided in a pharmaceutical preparation, as described
herein.
[0101] The pharmaceutical preparations of the present invention can
be administered in a wide variety of ways to the host, such as, for
example, orally enterally, nasally, parenterally, intramuscularly
or intravenously, rectally, vaginally, topically, ocularly,
pulmonarily, or by contact application. In a preferred embodiment,
a pharmaceutical protein expressed in a sprout is administered to a
host orally. In another preferred embodiment a pharmaceutically
active protein expressed in a sprout is extracted and/or purified,
and used for the preparation of a pharmaceutical composition.
Proteins are isolated and purified in accordance with conventional
conditions and techniques known in the art. These include methods
such as extraction, precipitation, chromatography, affinity
chromatography, electrophoresis, and the like.
[0102] The compositions of the present invention typically include
an effective amount of a pharmaceutically active protein together
with one or more organic or inorganic, liquid or solid,
pharmaceutically suitable carrier materials. A pharmaceutically
active protein produced according to the present invention is
employed in dosage forms such as tablets, capsules, troches,
dispersions, suspensions, solutions, capsules, creams, ointments,
aerosols, powder packets, liquid solutions, solvents, diluents,
surface active agents, isotonic agents, thickening or emulsifying
agents, preservatives, solid bindings as long as the biological
activity of the protein is not destroyed by such dosage form).
Other examples of materials that can serve as pharmaceutically
acceptable carriers include, but are not limited to sugars such as
lactose, glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil; safflower oil; sesame oil; olive oil; corn oil and soybean
oil; glycols; such a propylene glycol; esters such as ethyl oleate
and ethyl laurate; agar; buffering agents such as magnesium
hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water;
isotonic saline; Ringer's solution; ethyl alcohol, and phosphate
buffer solutions, as well as other non-toxic compatible lubricants
such as sodium lauryl sulfate and magnesium stearate, as well as
coloring agents, releasing agents, coating agents, sweetening
agents, flavoring agents, and perfuming agents, preservatives, and
antioxidants can also be present in the composition, according to
the judgment of the formulator (see also Remington's Pharmaceutical
Sciences, Fifteenth Edition, E.W. martin (Mack Publishing Co.,
Easton Pa., 1975). For example, the protein may be provided as a
pharmaceutical composition by means of conventional mixing
granulating dragee-making, dissolving, lyophilizing, or similar
processes.
[0103] In certain preferred embodiments it may be desirable to
prolong the effect of a pharmaceutical preparation by slowing the
absorption of the pharmaceutical protein that is subcutaneously or
intramuscularly injected. This may be accomplished by the use of a
liquid suspension of crystalline or amorphous material with poor
water solubility. The rate of absorption of the protein then
depends upon its rate of dissolution, which in turn, may depend
upon size and form. Alternatively, delayed absorption of a
parenterally administered protein is accomplished by dissolving or
suspending the protein in an oil vehicle. Injectable depot forms
are made by forming microencapsule matrices of the protein in
biodegradable polymers such as polylactide-polyglycolide. Depending
upon the ratio of protein to polymer and the nature of the
particular polymer employed, the rate of release can be controlled.
Examples of other biodegradable polymers include poly(orthoesters)
and poly(anhydrides). Depot injectable formulations are also
prepared by entrapping the protein in liposomes or microemulsions,
which are compatible with body tissues.
[0104] Enterally administered protein preparations may be
introduced in solid, semi-solid, suspension or emulsion form and
may be compounded with any pharmaceutically acceptable carriers,
such as water, suspending agents, and emulsifying agents. The
proteins of the invention may also be administered by means of
pumps or sustained-release forms, especially when administered as a
preventive measure, so as to prevent the development of disease in
a subject or to ameliorate or delay an already established
disease.
[0105] The sprouted seedlings or pharmaceutically active proteins
produced according to the present invention are particularly well
suited for oral administration as pharmaceutical compositions. The
harvested seedlings may be processed in a variety of ways, e.g.,
air drying, freeze drying, extraction etc., depending on the
properties of the desired protein product and the desired form of
the final product. In preferred embodiments, such compositions as
described above are ingested orally alone or ingested together with
food or feed or a beverage. Compositions for oral administration
include sprouted seedlings; extractions of the sprouted seedlings,
and proteins purified from sprouted seedlings provided as dry
powders, foodstuffs, aqueous or non-aqueous solvents, suspensions,
or emulsions. Examples of non-aqueous solvents are propylene
glycol, polyethylene glycol, vegetable oil, fish oil, and
injectable organic esters. Aqueous carriers include water,
water-alcohol solutions, emulsions or suspensions, including saline
and buffered medial parenteral vehicles including sodium chloride
solution, Ringer's dextrose solution, dextrose plus sodium chloride
solution, Ringer's solution containing lactose or fixed oils.
Examples of dry powders include any sprouted seedling biomass that
has been dried, for example, freeze dried, air dried, or spray
dried. For example, the seedlings may be air dried by placing them
in a commercial air dryer at about 120 degrees Fahrenheit until the
biomass contains less than 5% moisture by weight. The dried
seedlings are stored for further processing as bulk solids or
further processed by grinding to a desired mesh sized powder.
Alternatively, freeze-drying may be used for products that are
sensitive to air-drying. Products may be freeze dried by placing
them into a vacuum drier and dried frozen under a vacuum until the
biomass contains less than about 5% moisture by weight. The dried
material can be further processed as described herein.
[0106] Herbal preparations are well known in the art. Herbal
preparations that may be used to administer the sprouts of the
present invention include liquid and solid herbal preparations.
Some examples of herbal preparations include tinctures, extracts
(e.g., aqueous extracts, alcohol extracts), decoctions, dried
preparations (e.g., air-dried, spray dried, frozen, or
freeze-dried), powders (e.g., lyophilized powder), and liquid.
Herbal preparations can be provided in any standard delivery
vehicle, such as a capsule, tablet, suppository, liquid dosage,
etc. Those skilled in the art will appreciate the various
formulations and modalities of delivery of herbal preparations that
may be applied to the present invention.
[0107] Those skilled in the art will appreciate that a particularly
preferred method of obtaining the desired pharmaceutically active
protein is by extraction. Fresh seedlings may be extracted to
remove the desired protein products from the residual biomass,
thereby increasing the concentration and purity of the product.
Seedlings may also be extracted in a buffered solution. For
example, the fresh harvested seedlings may be transferred into an
amount of ice-cold water at a ratio of one to one by weight that
has been buffered with, e.g., phosphate buffer. Protease inhibitors
can also be added as required. The seedlings can be disrupted by
vigorous blending or grinding while suspended in the buffer
solution and the extracted biomass removed by filtration or
centrifugation. The protein product carried in solution can be
further purified by additional steps or converted to a dry powder
by freeze-drying or precipitation. Extraction can also be carried
out by pressing. Live seedlings can also be extracted by pressing
in a press or by being crushed as they are passed through closely
spaced rollers. The fluids expressed from the crushed plants are
collected and processed according to methods well known in the art.
Extraction by pressing allows the release of the products in a more
concentrated form. However, the overall yield of the product may be
lower than if the product were extracted in solution.
[0108] The sprouted seedlings, extractions, powders, dried
preparations and purified protein products, etc., can also be in
encapsulated form with or without one or more excipients as noted
above. The solid dosage forms of tablets, dragees, capsules, pills,
and granules can be prepared with coatings and shells such as
enteric coatings, release controlling coatings and other coatings
well known in the pharmaceutical formulating art. In such solid
dosage forms the active pharmaceutical protein may be admixed with
at least one inert diluent such as sucrose, lactose or starch. Such
dosage forms may also comprise, as is normal practice, additional
substances other than inert diluents, e.g., tableting lubricants
and other tableting aids such a magnesium stearate and
microcrystalline cellulose. In the case of capsules, tablets and
pills, the dosage forms may also comprise buffering agents. They
may optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes.
[0109] In other particularly preferred embodiments, a sprout
expressing a pharmaceutically active protein of the present
invention or biomass of sprouted seedlings is administered orally
as medicinal food. Such edible compositions are consumed by eating
raw, if in a solid form, or by drinking, if in liquid form. In a
preferred embodiment, the plant material is directly ingested
without a prior processing step or after minimal culinary
preparation. For example, the pharmaceutically active protein is
expressed in a sprout of which can be eaten directly. For example,
the protein is expressed in an alfalfa sprout, mung bean sprout, or
spinach or lettuce leaf sprout, etc. In an alternative embodiment,
the sprouted seedling biomass is processed and the material
recovered after the processing step is ingested.
[0110] Processing methods preferably used in the present invention
are methods commonly used in the food or feed industry. The final
products of such methods still include a substantial amount of the
expressed pharmaceutically active protein and are preferably
conveniently eaten or drunk. The final product may also be mixed
with other food or feed forms, such as salts, carriers, favor
enhancers, antibiotics, and the like, and consumed in solid,
semi-solid, suspension, emulsion, or liquid form. In another
preferred embodiment, such methods include a conservation step,
such as, e.g., pasteurization, cooking, or addition of conservation
and preservation agents. Any plant is used and processed in the
present invention to produce edible or drinkable plant matter. The
amount of pharmaceutically active protein in an edible or drinkable
sprout preparation may be tested by methods standard in the art,
e.g., gel electrophoresis, Elisa, or Western blot analysis, using
an antibody specific for the protein. This determination is used to
standardize the amount of protein ingested. For example, the amount
of therapeutically active protein in a sprout juice determined and
regulated, for example, by mixing batches of product having
different levels of protein so that the quantity of juice to be
drunk to ingest a single dose can be standardized. The contained,
regulatable environment of the present invention, however, should
minimize the need to carry out such standardization procedures.
[0111] A pharmaceutically active protein produced in a sprouted
seedling and eaten by a host is absorbed by the digestive system.
One advantage of the ingestion of a sprouted seedling or sprouted
seedling preparation, particularly intact sprouts or sprout biomass
that has been only minimally processed, is to provide encapsulation
or sequestration of the protein in cells of the plant. Thus, the
protein may receive at least some protection from digestion in the
upper digestive tract before reaching the gut or intestine and a
higher proportion of active would be available for uptake.
[0112] The pharmaceutical compositions of the present invention can
be administered therapeutically or prophylactically. In certain
preferred embodiments, the compositions may be used to treat or
prevent a disease. For example, any individual who suffers from a
disease or who is at risk of developing a disease may be treated.
It will be appreciated that an individual can be considered at risk
for developing a disease without having been diagnosed with any
symptoms of the disease. For example, if the individual has a
particular genetic marker identified as being associated with
increased risk for developing a particular disease, that individual
will be considered at risk for developing the disease. Similarly,
if members of an individual's family have been diagnosed with a
particular disease, e.g., cancer, the individual may be considered
to be at risk for developing that disease.
[0113] Liquid dosage forms for oral administration include, but are
not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups, and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0114] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compositions of this invention with suitable non-irritating
excipients or carriers such as cocoa butter, polyethylene glycol or
a suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active protein.
[0115] Dosage forms for topical or transdermal administration of a
pharmaceutical composition of this invention include ointments,
pastes, creams, lotions, gels, powders, solutions, sprays,
inhalants or patches. The active protein, or preparation thereof,
is admixed under sterile conditions with a pharmaceutically
acceptable carrier and any needed preservatives or buffers as may
be required. Ophthalmic formulation, eardrops, and eye drops are
also contemplated as being within the scope of this invention.
Additionally, the present invention contemplates the use of
transdermal patches, which have the added advantage of providing
controlled delivery of a pharmaceutically active protein to the
body. Such dosage forms can be made by suspending or dispensing the
pharmaceutically active protein in the proper medium. Absorption
enhancers can also be used to increase the flux of the
pharmaceutically active protein across the skin. The rate can be
controlled by either providing a rate controlling membrane or by
dispersing the pharmaceutically active protein in a polymer matrix
or gel.
[0116] The compositions are administered in such amounts and for
such time as is necessary to achieve the desired result. As
described above, in certain embodiments of the present invention a
"therapeutically effective amount" of a pharmaceutical composition
is that amount effective for treating, attenuating, or preventing a
disease in a host. Thus, the "amount effective to treat, attenuate,
or prevent disease", as used herein, refers to a nontoxic but
sufficient amount of the pharmaceutical composition to treat,
attenuate, or prevent disease in any host. As but one example, the
"therapeutically effective amount" can be an amount to treat,
attenuate, or prevent diabetes.
[0117] The exact amount required will vary from subject to subject,
depending on the species, age, and general condition of the
subject, the stage of the disease, the particular pharmaceutical
mixture, its mode of administration, and the like. The sprouted
seedlings of the invention and/or protein preparations thereof are
preferably formulated in dosage unit form for ease of
administration and uniformity of dosage. The expression "dosage
unit form," as used herein, refers to a physically discrete unit of
pharmaceutically active protein appropriate for the patient to be
treated. It will be understood, however, that the total daily usage
of the compositions of the present invention are preferably decided
by an attending physician within the scope of sound medical
judgment. The specific therapeutically effective dose level for any
particular patient or organism will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed; the
specific composition employed; the age, body weight, general
health, sex of the patient, diet of the patient, pharmacokinetical
condition of the patient, the time of administration, route of
administration, and rate of excretion of the specific compound
employed; the duration of the treatment; drugs used in combination
or coincidental with the specific compound employed; and like
factors well known in the medical arts.
[0118] It will also be appreciated that the pharmaceutical
compositions of the present invention can be employed in
combination therapies, that is, the pharmaceutical compositions can
be administered concurrently with, prior to, or subsequent to, one
or more other desired therapeutics or medical procedures. The
particular combination of therapies (therapeutics or procedures) to
employ in a combination regimen will take into account
compatibility of the desired therapeutics and/or procedures and the
desired therapeutic effect to be achieved. It will also be
appreciated that the therapies employed may achieve a desired
effect for the same disorder (for example, an inventive compound
may be administered concurrently with another anti-cancer agent),
or they may achieve different effects.
Kits
[0119] In still another aspect, the present invention also provides
a pharmaceutical pack or kit including the live sprouted seedlings
of the present invention or preparations, extracts, or
pharmaceutical compositions containing the pharmaceutically active
protein expressed by the sprouted seedlings in one or more
containers filled with one or more of the ingredients of the
pharmaceutical compositions of the invention. In certain
embodiments, the pharmaceutical pack or kit includes an additional
approved therapeutic agent for use as a combination therapy.
Optionally associated with such container(s) can be a notice in the
form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceutical products, which notice
reflects approval by the agency of manufacture, use, or sale for
human administration.
[0120] The present invention involves the purification and
affordable scaling up of the production of pharmaceutical proteins
from sprouted seedlings using any of a variety of plant expression
systems, most preferably viral plant expression systems. Kits are
provided that include each protein in a diagnostic kit for genetic
and immunologic diseases. In one preferred embodiment, the present
invention provides kits having test samples of biological proteins
and reagents for testing for the presence of antibodies in a
patient's serum to those biological proteins. For example, the kit
may provide IA-2 and GAD and reagents to test for the presence of
excess amounts of antibodies to these proteins in a patient's
serum, a clear indication of the presence or development of type 1
diabetes.
[0121] The present invention can be extended to provide diagnostic
reagents in the form of a kit. As but one non-limiting example, the
proteins insulin, GAD, and IA-2, associated with the autoimmune
reaction in diabetes, can be provided as oral formulations and
administered to induce oral tolerance to these proteins.
Alternatively, one or more therapeutic protein can be provided in
an injectable formulation or vaccine for administration. According
to preferred embodiments, pharmaceutical doses or instructions
therefor are provided in the kit for administration to an
individual diagnosed with a disease, e.g., a diabetic individual,
or an individual at risk for developing a disease, e.g., type 1
diabetes.
Equivalents
[0122] The representative examples that follow are intended to help
illustrate the invention, and are not intended to, nor should they
be construed to, limit the scope of the invention. Indeed, various
modifications of the invention and many further embodiments
thereof, in addition to those shown and described herein, will
become apparent to those skilled in the art from the full contents
of this document, including the examples which follow and the
references to the scientific and patent literature cited herein. It
should further be appreciated that the contents of those cited
references are incorporated herein by reference to help illustrate
the state of the art. The following examples contain important
additional information, exemplification and guidance, which can be
adapted to the practice of this invention in its various
embodiments and the equivalents thereof.
Examples
Example 1
Production of Pharmaceuticals in Sprouts by Agrobacterium
Transformation
[0123] Seeds of plants are transformed by Agrobacterium are
harvested, dried, cleaned, and tested for viability and presence of
desired genetic material. Seed stock is stored under appropriate
conditions until use. At the time of use, appropriate amounts of
seeds are soaked in water containing an amount of surface
sterilizing agent (e.g., Clorox) for 20 minutes to 4 hours. Seeds
are spread onto a flat of trays, which contain provisions for
sustenance of growth and drainage of water. Trays containing the
seeds are put on racks in the contained, regulatable environment
under controlled temperature, lighting, access, air circulation,
water supply, and drainage. Trays are misted with water from
misters equipped with automatic timers for one to 30 minutes at
intervals of 30 minutes to four hours, sufficient to keep seeds
damp. Excess moisture drains through holes in the trays into drains
in the floor of the room.
[0124] Seeds are allowed to germinate and develop under controlled
conditions. Seeds are incubated for about two to fourteen days
before harvest and processing. At some point during the incubation
process, from four hours to seven days prior to harvest, seeds are
exposed to environmental conditions that cause the induction of an
introduced or indigenous DNA promoter sequence that causes an
increase in the synthesis of one or more desired proteins in the
tissues of the sprouting seedling. A transient increase in the
incubation temperature from about 30.degree. C. to about 37.degree.
C. to cause induction of a heat shock promoter.
[0125] After incubation of the seedlings for two to fourteen days,
the seedlings are harvested by moving the individual trays into a
processing facility on a conveyor belt. The harvested seedlings are
processed by extraction in phosphate buffered solution containing
protease inhibitors. The seedlings are disrupted by vigorous
blending or grinding while suspended in the buffer solution and the
extracted biomass removed by centrifugation.
Example 2
Sprouts of Seedlings Transiently Infected by a Plants Virus
[0126] Seeds of desired plants are obtained from a contract of
commercial grower as wild-type seeds. The seed stock is stored
under appropriate conditions of temperature, humidity, sanitation,
and security until use. At the time of use, appropriate amounts of
seeds are soaked in water and incubated on trays as described above
under controlled conditions.
[0127] After incubation for two to fourteen days, the germinated
seedlings are sprayed with a solution containing a virus harboring
a transgene, and further or simultaneously treated with a material
that causes mechanical abrasion of the plant leaf tissue. In this
example, the leaves are abraded with a spray of air containing
abrasive particles. The virus is allowed to systemically infect the
plants for an appropriate period; from about one to about ten days
and expression of the desired heterologous protein is
monitored.
[0128] After infection of the seedlings for one to ten days, the
seedlings are harvested as described in Example 1 above.
Example 3
Expression of Diabetes Associated Proteins and Human Growth Hormone
in Plants
[0129] Early onset Type 1 or juvenile diabetes is a disease that
affects children, adolescents, and young adults. Beta islet cells
of the pancreatic endocrine system produce insulin in response to
the metabolic signal of high blood glucose. The underlying etiology
of the disease is the attack and destruction of the beta islet
cells by the body's own immune system.
[0130] Individuals with type 1 diabetes produce antibodies against
at least three proteins that are normally found in all individuals,
i.e., insulin, glutamic acid decarboxylase (GAD), and the
tyrosine-phosphatase-like protein IA-2 (Leslie et al., Diabetologia
(1999) 42:30-14). Autoantibodies to the IA-2 and GAD proteins are
found in 50 to 75% of type 1 diabetes patients prior to onset of
the disease. In addition, the appearance of autoantibodies against
these seemingly normal proteins occurs 7 to 8 years ahead of onset
of the classical symptoms associated with type 1 diabetes.
[0131] Autoantigens such as insulin, GAD and IA-2 are useful in
inducing at least a degree of oral tolerance to these proteins in
susceptible individuals and prevent or reduce the damage to islet
cells that results in the development of diabetes. Non-obese
diabetic mice (NOD) spontaneously develop an autoimmune form of
diabetes (Zahang, et al., Proc. Natl. Acad. Sci. USA (1991)
88:10252-10256). The gene encoding human insulin has been fused
with the cholera toxin B subunit gene and the resulting construct
expressed in transgenic potato plants. When these plants were fed
to NOD mice, the animals showed a substantial reduction in
pancreatic islet inflammation and a delay in the progression of
diabetes (Arakawa et al., Nat. Biotechnol. (1998) 16:934-936). The
GAD protein has also been expressed in potato plants. These
transgenic potatoes, when fed to NOD mice, also either prevented or
significantly delayed the onset of diabetes after 40 weeks (Ma et
al., Nature Medicine (1997) 3:793-796).
[0132] In this example, certain non-limiting conditions for
expression and recovery of GAD and IA-2 from plants are described.
The GAD and IA-2 proteins are purified suing the His-tag method.
Production of raw material and proteins takes place in two stages:
1) small scale (mg quantities) for preliminary studies in animals;
and 2) medium scale (gram quantities for clinical trials.
Materials and Methods:
[0133] Testing the stability and movement. To conduct viral
stability and movement tests, small quantities of each construct
are synthesized Each construct contains a T7 or SP6 RNA polymerase
promoter fused to the exact 5' terminus of viral genomic RNA and a
unique restriction site at the 3' end that is used to linearize the
plasmid prior to in vitro transcription. The T7 or SP6 RNA
polymerase then generates run-off transcripts, which are used to
inoculate plants. Plants are inoculated mechanically at two-leaf
stage, by gently rubbing the inoculum onto the leaf surface in the
presence of an abrasive agent, such as carborundum powder
(320-grit; Fisher, Pittsburgh, Pa.). Five to ten plants are
inoculated per construct and 1-2 .mu.g of each RNA transcript is
used per inoculation. The plants are monitored for severity of
symptoms, spread of virus throughout entire plant, and product
recovery. At 10-15 days post infection (dpi) leaf samples from
infected leaf samples are harvested to assess the presence of
full-size recombinant IA-2 and GAD. A portion of the harvested
material (10 leaves) is frozen in -80.degree. C. and retained as a
seed inoculum for the subsequent production scale-up of selected
constructs. The rest of the tissue is processed immediately.
[0134] At 15-20 days post infection (dpi) recombinant IA-2 and GAD
are recovered. The procedure is optimized to recover optimum
quantities of high purity product (90-95% purity). Once products
with the expected sizes are recovered and serological identity
(recognized by specific antibodies using Western blot and ELISA)
determined, the stability of the constructs is tested by three
passages on healthy plants. Problems with assembly, recovery or
stability of recombinant virus with proteins in the size range
employed are manage at the level of nucleotide sequence or amino
acid sequence by changing the conditions of infection or by using
an alternative host plant.
[0135] Establishing seed-lot and procedures for medium scale
production. When stage 1 is completed, a small quantity (100 ul) of
in vitro synthesized transcripts of the recombinant constructs is
prepared and used to inoculate 10 plants. Within 10-12 days after
inoculation the leaves are harvested, tested for the presence of
GAD or IA-2 by Western blot, and stored at -70.degree. C. as seed
material. A portion of this material (3-4) is used to inoculate
150-200 plants (1-2 kg of fresh tissue). Fifteen to twenty days
after inoculation, recombinant protein is recovered and used for
functional studies. An average of 60 mg of product per batch is
expected.
[0136] Plant inoculation and product recovery. In vitro transcripts
of recombinant virus containing GAD and IA-2 are synthesized using
T7 RNA polymerase and purified plasmid DNA. Transcripts are capped
using the RNA cap structure analog m7G(5)ppp(5)G. For inoculation,
a mixture of in vitro transcription products is applied to the
leaves of the target host plants after abrading the leaf surface
with carborundum and gently rubbing on the leaf surface to spread
the inoculum and further abrade the surface. The purity and
activity of the plant produced IA-1 and GAD are tested. The
antibody binding capacity of the plant-produced antigens is tested
by ELISA during and after purification of the proteins.
[0137] Protein expression in Nicotiana benthamiana: To express
full-length proteins in virus-infected plants, we used a functional
complementation approach to express green fluorescent protein (GFP)
from jellyfish in N. benthamiana plants (FIG. 4). During
plant-to-plant passages, the amount of Alfalfa mosaic virus
(Av)/GFP in the infected tissue gradually decreased and after the
third transfer, only Av/A4 was detectable. (This is an advantage
from an environmental safety point of view.) Using this approach,
we could express an average of 100 .mu.g of GFP per gram fresh
tissue. An important component of this system, Alfalfa mosaic virus
CP, is unique in its ability to encapsidate the genomic RNAs of
unrelated viruses into infectious particles in the infected host.
This unique ability of Alfalfa mosaic virus CP is exploited to
engineer hybrid vectors that specifically target selected crop
species.
[0138] Expression of recombinant GFP in Nicotiana benthamiana
plants inoculated with Av/A4 and Av/A4GFP was analyzed by Western
Blot (see FIG. 3). Protein extracts from leaves infected
systematically as described herein were separated by
electrophoresis on a 12% SDS-polyacrylamide gel, transferred to a
nitrocellulose membrane and reacted with protein-specific
antibodies. Alfalfa mosaic virus CP-specific antibodies recognized
the expected size protein (24.0 kD) in plants inoculated with Av/A4
or with the mixture of Av/A4 and Av/A4GFP. GFP-specific antibodies
recognized protein only in extracts from plants inoculated with the
mixture of Av/A4 and Av/A4GFP. GFP-specific antibodies did not
react with any proteins in plants inoculated with only Av/A4.
Neither Alfalfa mosaic virus CP- nor GFP-specific antibodies
reacted with any protein in extracts from plants inoculated with
Av/GFP only, suggesting the lack of systemic movement.
[0139] We have also engineered and expressed human growth hormone
using this Av/A4 vector system. Nicotiana benthamiana plants were
inoculated with in vitro transcripts and the plants monitored for
production of hGH. No signal specific to the protein could be
detected at 5 dpi (days post inoculation), although at 11 dpi we
could detect a signal for hGH in the inoculated plants. FIG. 4 is a
Western Blot of hGH produced in N. benthamiana plants infected with
in vitro transcripts of 125C/hGH. Samples were analyzed 24 hours
post inoculation. 1 .mu.g of purified hGH was loaded as standard.
MWM is molecular weight marker. The arrow in FIG. 4 points toward
the hGH band on the blot detected by hGH-specific antibodies.
Example 4
Expression of Anthrax Associated Proteins and Human Growth Hormone
in Plants
[0140] The virulence of anthrax is due to at least two major
virulence factors. These factors are a polyglutamate capsule that
helps protect the bacterium in the host and a three-part
circulating toxin. Anthrax toxin is encoded by a 184 kb plasmid
named pXO1 and consists of a receptor-binding protein named
protective antigen (PA), and two enzymatically active proteins
named edema factor and lethal factor (Bhatnagar and Batra. Crit.
Rev. Mirobiol. (2001) 27(3):167-200).
[0141] In this example, two inactivated anthrax toxin components,
protective antigen (PA) and lethal factor (LF) are produced in the
leaves of Brassica juncea at concentration of at least 0.1 mg/gm
dry weight. We have optimized the codon usage of these genes for
plants and changed the amino acid sequences to minimize toxicity
for both toxin molecules. We propose to insert the synthesized DNA
into vectors capable of regulated gene expression in Brassica
juncea. The PA gene was altered to delete phenylalanine residues at
positions 314 and 315. The LF gene has an alanine substituted for a
histidine at position 686 or position 690 (see, e.g., Singh et al.,
J. Biol. Chem. (1994) 269:29039-29046; Klimpel et al., Mol.
Microbiol. (1994) 13: 1093-1097).
[0142] Transformation vector: The binary vector pGREENII 0229
(Hellens et al., Plant Molecular Biology (April 2000)
42(6):819-832) is used for plant transformation (see FIG. 5). This
plasmid includes the following components. 1) The pGREENII plasmid
backbone includes sequences necessary for replication in
Escherichia coli and Agrobacterium tumefaciens. 2) The
Agrobacterium tumefaciens T-DNA left and right border (LB and RB)
sequences are necessary for integration of all sequences between LB
and RB into the plant genome. 3) The npt gene encoding kanamycin
resistance for selection of Escherichia coli and Agrobacterium
tumefacients tranformants. 4) The nos-bar gene, which encodes
resistance to the herbicide Bialaphos (resistance to Bialophos is
used to select transgenic plants. The nos-bar gene is transcribed
from the Cauliflower mosaic virus (CAMV) 35S promoter with
constitutive activity in plants, and transcription of the gene is
terminated using the CaMV terminator. 5) Expression of vir genes PA
and LF are driven either by the CAMV 35S promoter as shown in FIG.
5, or by the HSP18.2 promoter (GenBank accession #X17295, locus
At5g59720) for the Arabidopsis thaliana low molecular weight heat
shock protein (Matsuhara et al., The Plant Journal: for Cell &
Molecular Biolog (April 2000) 22(1):79-86). Transcriptional
termination is mediated by the terminator of the nopaline synthase
gene (nos). The 35S and HSP18.2 promoters where chosen for their
differing activities. The 35S promoter is constitutively active in
most plant tissues. In many cases the 35S promoter drives
high-level expression of the protein of interest. By contrast the
HSP18.2 promoter is nearly inactive unless the plants are
challenged by heat shock. High-level expression of some proteins
can only be achieved using an inducible promoter system.
[0143] Vector construction and plant transformation. The vectors
are constructed using DH5, a laboratory strain of Escherichia coli.
The construction is analyzed by restriction endonuclease mapping
and sequencing. After construction is confirmed the vector is used
to transform Agrobacterium tumefaciens strain GV3101, lacking a
native Ti plasmid and suitable for transfer of the TDNA of binary
vectors into plants. Brassica juncea plants are transformed by
introduction of GV3101 carrying the transformation vector into
flowers by any available transformation method.
[0144] Modifications introduced into PA and LF genes. The
nucleotide sequences of both PA and LF are modified for expression
in plants. The coding sequence of native PA is 2295 by and native
LF is 2430 bp. These sequences are modified as follows: 1)
Mutations are introduced that render PA and LF inactive as toxins.
Phe314 and Phe315 are deleted from PA and His686 and His690 are
mutated to Ala. 2) Codon usage is optimized for expression in
Brassica juncea. Since the codon usage and GC/AT ratio of Brassica
juncea is neutral the changes introduced into PA and LF are not
extensive. Four codons are changed in PA and seven in LF. 3) Unique
restriction sites are added to the 5' and 3' ends of the genes for
cloning into the plant expression vector. [4] A consensus sequence
for translation initiation will be added (Joshi et al., Plant
Molecular Biology. (December 1997) 35(6):993-1001). The restriction
sites and optimized translation initiation site are illustrated in
FIG. 5. The 5' end shows the added XbaI restriction site and the
consensus translation initiation site for plant genes, which
includes the initiation codon followed by an Ala codon. The 3' end
shows the added Sad restriction site. The modified PA and LF genes
are chemically synthesized by Entelechon, Inc. (Regensburg,
Germany).
[0145] A second construction is also produced for PA and LF. The
intention of the second construct is to optimize the accumulation
for PA and LF by targeting and retaining the proteins in the
endoplasmic reticulum.sup.40. Targeting and retention in the ER has
the potential to produce high-level accumulation of a recombinant
protein (Haseloff, et al., Proceedings of the National Academy of
Sciences USA. (Mar. 18, 1997) 94(6):2122-2127). To achieve this, an
amino-terminal signal sequence and a carboxyl terminal ER retention
sequence is added. The signal sequence includes 22 codons derived
from the Arabidopsis thaliana chitinase gene (Haseloff, et al.,
supra). The ER retention sequence is the tetrapeptide HisAspGluLeu
(Gomord et al, The Plant Journal: for Cell & Molecular Biology.
(February 1997) 11(2):313-325). The signal sequence is added by PCR
stitching using the synthetic genes produced by Entelechon as
templates (Tomme et al., J Bacteriol. (1995) 177:4356-4363). The ER
retention sequence is added by PCR amplification of the PA and LF
genes using a 3' primer into which the HisAspGluLeu coding sequence
has been incorporated. Modified PA and LF sequences are cloned into
35S and HSP18.2 expression vectors. Two modified version of each PA
and LF (a total of 4) are cloned. In total, 8 different
constructions are tested.
[0146] Selection and analysis of plants expressing transgenes.
After transformation of Brassica juncea with Agrobacterium
tumefaciens strain GV3101 carrying the transformation construct the
plants are allowed to progress through their normal developmental
program. Within 25 days, mature seeds are produced, dried, and
harvested. The seeds are sown in potting soil and seedling plants
are grown for 15 days. The leaves of each plant are then sprayed
with a 0.0058% (w/v) solution of Bialophos (FINALE, Farnam, Inc.,
Phoenix, Ariz.). Sensitive, non-transgenic plants are typically
killed within 5 to 7 days. Bialophos-resistant plants are evident
by their green and healthy appearance. The putative transgenic
plants are confirmed and analyzed using a series of protocols.
Polymerase chain reaction using oligonucleotide primers specific
for the construct are used to confirm the presence of the TDNA in
putative transgenic plants. The presence of the TDNA is then be
examined by blotting of genomic DNA using a specific DNA probe, the
modified PA or LF genes. Finally, expression of the protein of
interest is examined by SDS-PAGE followed by staining with
Coomassie Blue or immunoblotting. The protocol for analysis of
protein expression differs depending upon the construct used to
produce the transgenic plant. Plants carrying 35S promoter
constructions are analyzed directly since expression from this
promoter is constitutive. Plants carrying the HSP18.2 promoter are
heat shocked before analysis. The kinetics of recombinant protein
expression might differ in different transgenic plants. Ultimately,
the induction conditions are optimized for each using standard
methods. However, for initial analysis it is possible to carry out
a standardized heat shock protocol that is established for
expression of other recombinant proteins in Brassica juncea.
[0147] FIG. 6 shows an immunoblot of transgenic Brassica juncea
expressing human growth hormone (hGH) under control of the HSP
18.,2 promoter. Transgenic Brassica juncea were grown in potting
mix. As shown in FIG. 6, a leaf weighing 1 to 3 grams fresh weight
was detached from the plant and placed in a petri dish containing a
filter paper moistened with water. The petri dish is covered and
placed in a high humidity, 37.degree. C. incubator for 1.5 hours.
The petri dish containing the leaf was then removed from the
incubator and placed for 5 hours in a 24.degree. C. growth chamber
under fluorescent lights at an intensity of 100 .mu.mol photons
m.sup.-2s.sup.-1. The plant material was then harvested and
analyzed by immunoblotting using a monoclonal antibody against hGH
(Sigma Chemical Co., Product #G-8523). The lower band is the 16 kDa
recombinant hGH. This band is not observed before heat shock. Lane
8 shows the results from a transgenic plant transformed with the
vector alone. The higher molecular weight band is a non-specific
reaction with the horseradish peroxidase-linked secondary antibody
used to detect immune-complexes. PA is predicted to be
approximately 88 kDa and LF 93 kDa.
[0148] After an initial screen for anthrax toxin expression a more
detailed analysis of expression is carried out. An ELISA method is
used to quantitate the level of expression. Further analysis is
carried out on subsequent plant generation. In order to avoid the
need to select for transgenic plants in subsequent generations it
is ultimately necessary to isolate transgenic lines that are
non-segregating for the TDNA construct. This is accomplished by
self-pollinating the primary transgenic plants, raising the
secondary generation plants to maturity, and testing the tertiary
generation for segregation of Bialophos resistance. Secondary
generation individuals are identified that are non-segregating.
Thereafter, progeny of non-segregating plants are bulked and used
for analysis of production scale conditions (e.g., 1,600 Kg per
month of dried biomass). For production scale the growth and
induction conditions are optimized for plants grown as seedlings.
At this point it is also desirable to characterize the insertion
site and TDNA copy number of elite lines and to characterize
expression at the level of mRNA expression.
Example 5
Expression of a GUS Reporter in Sprouts
[0149] pBI121 containing a GUS reporter gene was transformed into
Agrobacterium tumefaciens LBA 4404. Bacterial cultures were grown
overnight in YEB medium containing 50 .mu.g/ml kanamycin, 20 .mu.M
acetosyringone and 10 mM MES pH 5.6. Overnight cultures were
centrifuged, resuspended in MMA medium (MS salts, 10 mM MES pH 5.6,
200 .mu.M acetosyringone and 2% sucrose) at OD.sub.600 2.0 and used
for vacuum infiltration of sprouts.
[0150] Seeds of various plants were imbibed in water for 24 hr at
room temperature on a rocking platform, transferred into plastic
containers with wet filter paper and incubated for 4 to 6 days
(depending on plant species) under 12 hr daylight at 21.degree.
C.
[0151] After vacuum infiltration, sprouts were incubated for
additional 48-60 hr under 12 hr daylight at 21.degree. C. and the
GUS activity was detected in situ using X-gluc histochemical
substrate. The staining was performed overnight at 37.degree. C.
and the plant samples were de-stained in ethanol. The system was
tested using a wide variety of sprouts. See FIGS. 8A and 8B and
FIG. 9.
Example 6
Expression of Diabetes Associated Proteins and Human Growth Hormone
Using Plant Virus Vector or Replicon Engineered into Agrobacterial
Expression System
[0152] We created a TMV-based vector in agrobacterial vector:
D4-hGH or D4-GFP. For this, we first had to create multiple cloning
sites in pBI121.
pBI121-Xba1-BamH1-Sal1-Pac1-BsiW1-Stu1-Xho1-Spe1-Kpn1-Sac1-pBI121-
. Using appropriate primers and PCR, we created pBI121 with these
sites. After confirming the sequence, we then proceeded to
introduce TMV genomic sequence into this plasmid. See also U.S.
Ser. No. 10/770,600 filed Feb. 3, 2004 and U.S. Provisional
application No. 60/444,615, filed Feb. 3, 2003, incorporated herein
by reference and U.S. Ser. No. 10/832,603 and U.S. provisional
application 60/546,339, incorporated herein by reference, for
further discussion of D4-hGH and D4-GFP. The parental vector, D4,
and vectors derived therefrom, are described in Shivprasad et al.,
Virology, 255(2):312-23, 1999. The resultant plasmid is referred to
as pBID4.
[0153] The 35S promoter of cauliflower mosaic virus was fused to
TMV sequence. Thus the 35S promoter directs transcription of the
TMV sequence. Upon successful incorporation into a cell, viral
transcripts are produced. In certain embodiments of the invention,
components needed for viral replication and spread throughout the
plant are also produced. These components include, e.g., replicase,
movement protein, and coat protein, which may be from TMV or from
another virus such as alfalfa mosaic virus in various embodiments.
These components may be encoded within the TMV sequence, the
plasmid sequence, provided in a separate viral vector or plasmid,
or the plant may be a transgenic plant comprising a transgene that
encodes the components. See, for example U.S. Ser. No. 10/770,600
filed Feb. 3, 2004, which is incorporated herein by reference.
[0154] A subgenomic TMV promoter within the TMV sequence directs
transcription of the hGH sequence. A hammerhead ribozyme was
introduced 3' of the TMV sequence. The ribozyme is not required for
the present invention. The nos terminator (well known in the art)
is 3' of the ribozyme sequence.
[0155] The final vector contained D4-hGH or D4-GFP. These
constructs in pBI121 were then used to transform A. tumefaciens and
plants infiltrated with transformed Agrobacterium. Since a
replicating virus is present we incubated the plants for 2 weeks.
Leaf discs were analysed for hGH production by Western blots. GFP
expression was monitored by illuminating the plants with long wave
ultraviolet light and photographed. The results shown in FIG. 10
deomonstrate GFP expression throughout the infiltrated leaves.
Western blot analysis shown in FIG. 11 using antibody directed to
hGH confirmed that the construct was functional in plants, and hGH
could be detected at high levels.
[0156] Similarly, IA-2ic was engineered into pBID4 plasmid to
generate pBID4-IA-2ic. Additionally, AMV viral based vector
carrying GFP was generated. Resulting plasmids was used to
transform Agrobacterium and hydroponically grown Nicotiana
benthamiana was infiltrated with transformed Agrobacterium.
Briefly, Nicotiana benthamiana seeds were sown on a Rockwool slab
(18.times.8.times.1) pre-wetted in 1/2 strength Hoagland solution
as a nutrient in hydroponic conditions. The hydroponics plants were
kept in the same solution for four weeks. Four week-old plants were
then vacuum infiltrated in Agrobacterium suspension (OD.sub.600
0.1) carrying pBID4-IA-2ic or AMV viral based vector carrying
GFP.
[0157] Bacterial cultures were grown and induced over night, then
cells were re-suspended in MMA medium (MS salts, 10 mM MES pH 5.6,
20 g/l sucrose, 200 .mu.M acetosyringone) to an OD.sub.600 of 0.1.
Re-suspended culture was incubated at room temperature for 2-3 h
with gentle shaking, and hydroponics Nicotiana benthamiana plants
were placed in the bacterial suspension, then vacuum was applied
for 30-60 second at room temperature. Vacuum was quickly released
to facilitate efficient infusion of the bacteria into the tissue,
and infiltrated plants were kept in 1/2 strength Hoagland solution
nutrient for 5-7 days Alternatively, the bacterial suspension was
forced under the epidermis of fully-expanded leaves, using a 10
cm.sup.2 syringe with no needle. Leaves were harvested between 3-6
days post-infiltration and stored at -80.degree. C. or analyzed for
expression analysis. FIG. 12 demonstrates western blot analysis of
plants expressing IA-2ic. Analysis of plants infiltrated with AMV
based GFP constructs under light demonstrated expression of GFP
throughout leaves of infiltrated plants.
Other Embodiments
[0158] Those of ordinary skill in the art will appreciate that the
foregoing represents certain preferred embodiments of the present
invention and should not be construed to limit the spirit or scope
of the invention as defined by the following claims:
Sequence CWU 1
1
2120DNAArtificial SequenceBrassica juncea 1tctagaaaac aatggctaaa
20215DNAArtificial SequenceBrassica juncea 2ataggataag agctc 15
* * * * *